ORIGINAL_ARTICLE
Pathophysiological mechanisms of gonadotropins– and steroid hormones–related genes in etiology of polycystic ovary syndrome
Objective(s): Polycystic ovary syndrome (PCOS) is an endocrinopathy in women, which, unlike its impact on fertility and health of women, there is no clear understanding about the causal mechanisms of this pathogenesis. The aim of this review paper is to investigate the pathophysiological pathways affecting the PCOS etiology, based on functions of gonadotropins– and steroid hormones–related genes.Materials and Methods: Due to different hormonal and metabolic signs of this complex disorder, different hypotheses are mentioned about etiology of this syndrome. Because of the heterogeneity of the reasons given for this syndrome and the spread of the effective genes in its pathophysiology, most of genes affected by sex-related hormonal imbalances are examined for discriminative diagnosis. For this purpose, published articles and reviews dealing with genetic evaluation of PCOS in women in peer-reviewed journals in PubMed and Google Scholar databases were included in this review.Results: In previous studies, it has been well demonstrated that PCOS in some individuals have a genetic origin. Pathophysiological functions of genes are primarily responsible for the synthesis of proteins that have role in PCOS before hyperandrogenism including GnRHR, FSHβ, FSHR, LHCGR, CYP19A1, HSD17B, AR and SHBG, and their effects in PCOS of human have been confirmed.Conclusion: Hormonal imbalances are the first reason mentioned in PCOS etiology, and usually characterized with menstrual irregularities in PCOS women. Hyperandrogenism and gonadotropin secretion disorders are shown in PCOS condition, which are related to steroidogenesis pathways and hypothalamic–pituitary–ovarian axis disturbances, respectively.
https://ijbms.mums.ac.ir/article_11818_f1883fb631e6dde9fbfcbbae1c54b742.pdf
2019-01-01
3
16
10.22038/ijbms.2018.31776.7646
Genes
Gonadotropins
Hormones
Hyperandrogenism
Polycystic ovary syndrome
Physiopathology
Steroids
Zahra
Shaaban
z.shaban91@yahoo.com
1
Department of Animal Science, College of Agriculture, Shiraz University, Shiraz, Iran
AUTHOR
Arezoo
Khoradmehr
mehrarezoo@gmail.com
2
Research and Clinical Center for Infertility, Yazd Reproduction Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
AUTHOR
Mohammad Reza
Jafarzadeh Shirazi
jafarzd@shirazu.ac.ir
3
Department of Animal Science, College of Agriculture, Shiraz University, Shiraz, Iran
AUTHOR
Amin
Tamadon
amintamaddon@yahoo.com
4
The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
LEAD_AUTHOR
1. De Leo V, Musacchio M, Cappelli V, Massaro M, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol 2016;14:38-54.
1
2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
2
3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006;91:4237-4245.
3
4. Fenichel P, Rougier C, Hieronimus S, Chevalier N. Which origin for polycystic ovaries syndrome: Genetic, environmental or both? Ann Endocrinol 2017;78:176-185.
4
5. Guo M, Chen Z, Eijkemans M, Goverde A, Fauser B, Macklon N. Comparison of the phenotype of Chinese versus Dutch Caucasian women presenting with polycystic ovary syndrome and oligo/amenorrhoea. Hum Reprod 2012;27:1481-1488.
5
6. Strauss III JF, McAllister JM, Urbanek M. Persistence pays off for PCOS gene prospectors. J Clin Endocrinol Metab 2012;97:2286-2288.
6
7. Deligeoroglou E, Kouskouti C, Christopoulos P. The role of genes in the polycystic ovary syndrome: predisposition and mechanisms. Gynecol Endocrinol 2009;25:603-609.
7
8. Roland AV, Moenter SM. Reproductive neuroendocrine dysfunction in polycystic ovary syndrome: insight from animal models. Front Neuroendocrinol 2014;35:494-511.
8
9. Shaaban Z, Jafarzadeh Shirazi MR, Nooranizadeh MH, Tamadon A, Rahmanifar F, Ahmadloo S, et al. Decrease in arginine-phenylalanine-amide-related peptide-3 gene expression of dorsomedial hypothalamic nucleus in constant light exposure model of polycystic ovarian syndrome. Int J Fertil Steril 2018;12:43-50.
9
10. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev 2016;37:467-520.
10
11. Luque-Ramírez M, San Millán JL, Escobar-Morreale HF. Genomic variants in polycystic ovary syndrome. Clin Chim Acta 2006;366:14-26.
11
12. Nestler JE. Modulation of aromatase and P450 cholesterol side-chain cleavage enzyme activities of human placental cytotrophoblasts by insulin and insulin-like growth factor I. Endocrinology 1987;121:1845-1852.
12
13. Sir-Petermann T, Maliqueo M, Angel B, Lara H, Perez-Bravo F, Recabarren S. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod 2002;17:2573-2579.
13
14. Kosova G, Urbanek M. Genetics of the polycystic ovary syndrome. Mol Cell Endocrinol 2013;373:29-38.
14
15. Roldán B, San Millán JL, Escobar-Morreale HF. Genetic basis of metabolic abnormalities in polycystic ovary syndrome. Am J Pharmacogenomics 2004;4:93-107.
15
16. Goodarzi MO, Azziz R. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Practice & Research: Clin Endocrinol Metabol 2006;20:193-205.
16
17. Barber TM, Franks S. Genetics of polycystic ovary syndrome. Front Horm Res 2013;40:28-39.
17
18. Jones MR, Goodarzi MO. Genetic determinants of polycystic ovary syndrome: progress and future directions. Fertil Steril 2016;106:25-32.
18
19. Chen Z-J, Zhao H, He L, Shi Y, Qin Y, Shi Y, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16. 3, 2p21 and 9q33. 3. Nat Genet 2011;43:55-59.
19
20. Shi Y, Zhao H, Shi Y, Cao Y, Yang D, Li Z, et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet 2012;44:1020-1025.
20
21. Day FR, Hinds DA, Tung JY, Stolk L, Styrkarsdottir U, Saxena R, et al. Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome. Nat Commun 2015;6:8464.
21
22. Welt CK, Styrkarsdottir U, Ehrmann DA, Thorleifsson G, Arason G, Gudmundsson JA, et al. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J Clin Endocrinol Metab 2012;97:E1342-E1347.
22
23. Brower MA, Jones MR, Rotter JI, Krauss RM, Legro RS, Azziz R, et al. Further investigation in europeans of susceptibility variants for polycystic ovary syndrome discovered in genome-wide association studies of Chinese individuals. J Clin Endocrinol Metab 2015;100:E182-E186.
23
24. Moore AM, Campbell RE. The neuroendocrine genesis of polycystic ovary syndrome: a role for arcuate nucleus GABA neurons. J Steroid Biochem Mol Biol 2016;160:106-117.
24
25. Carmel P, Araki S, Ferin M. Pituitary stalk portal blood collection in rhesus monkeys: evidence for pulsatile release of gonadotropin-releasing hormone (GnRH). Endocrinology 1976;99:243-248.
25
26. Barzegar MH, Khazali H, Kalantar SM, Khoradmehr A. The comparative effect of Citrullus colocynthis hydro-alcoholic extract (CCT) and metformin on morphometric ovarian follicles disorders in estradilol valerate Iinduced PCOS rats. Galen Med J 2018;7:In press.
26
27. Medissa H, Hunter J. Polycystic ovary syndrome: its not just infertility. Am Fam Physician 2000;62:1079-1088.
27
28. Shoham Z, Jacobs HS, Insler V. Luteinizing hormone: its role, mechanism of action, and detrimental effects when hypersecreted during the follicular phase. Fertil Steril 1993;59:1153-1161.
28
29. Dufau ML. The luteinizing hormone receptor. Annu Rev Physiol 1998;60:461-496.
29
30. Almawi WY, Hubail B, Arekat DZ, Al-Farsi SM, Al-Kindi SK, Arekat MR, et al. Leutinizing hormone/choriogonadotropin receptor and follicle stimulating hormone receptor gene variants in polycystic ovary syndrome. J Assist Reprod Genet 2015;32:607-614.
30
31. Sheikhha MH, Kalantar SM, Ghasemi N. Genetics of polycystic ovary syndrome. Int J Reprod BioMed 2007;5:1-5.
31
32. Ubuka T, Morgan K, Pawson AJ, Osugi T, Chowdhury VS, Minakata H, et al. Identification of human GnIH homologs, RFRP-1 and RFRP-3, and the cognate receptor, GPR147 in the human hypothalamic pituitary axis. PLoS ONE 2009;4:e8400.
32
33. Tian Y, Zhao H, Chen H, Peng Y, Cui L, Du Y, et al. Variants in FSHB are associated with polycystic ovary syndrome and luteinizing hormone level in Han Chinese women. J Clin Endocrinol Metab 2016;101:2178-2184.
33
34. Caburet S, Fruchter RB, Legois B, Fellous M, Shalev S, Veitia RA. A homozygous mutation of GNRHR in a familial case diagnosed with polycystic ovary syndrome. Eur J Endocrinol 2017;176:K9-K14.
34
35. Li Q, Yang G, Wang Y, Zhang X, Sang Q, Wang H, et al. Common genetic variation in the 3′-untranslated region of gonadotropin-releasing hormone receptor regulates gene expression in cella and is associated with thyroid function, insulin secretion as well as insulin sensitivity in polycystic ovary syndrome patients. Hum Genet 2011;129:553-561.
35
36. Batista MCP, de Fatima Duarte E, dos Reis Borba MD, Zingler E, Mangussi-Gomes J, dos Santos BTA, et al. Trp28Arg/Ile35Thr LHB gene variants are associated with elevated testosterone levels in women with polycystic ovary syndrome. Gene 2014;550:68-73.
36
37. El‐Shal AS, Zidan HE, Rashad NM, Abdelaziz AM, Harira MM. Association between genes encoding components of the Leutinizing hormone/Luteinizing hormone–choriogonadotrophin receptor pathway and polycystic ovary syndrome in Egyptian women. IUBMB life 2016;68:23-36.
37
38. Hayes MG, Urbanek M, Ehrmann DA, Armstrong LL, Lee JY, Sisk R, et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun 2015;6:7502.
38
39. Liaqat I, Jahan N, Krikun G, Taylor HS. Genetic polymorphisms in Pakistani women with polycystic ovary syndrome. Reprod Sci 2015;22:347-357.
39
40. Goodarzi MO, Jones MR, Li X, Chua AK, Garcia OA, Chen Y-DI, et al. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J Med Genet 2011;49:90-95.
40
41. Eriksen MB, Brusgaard K, Andersen M, Tan Q, Altinok ML, Gaster M, et al. Association of polycystic ovary syndrome susceptibility single nucleotide polymorphism rs2479106 and PCOS in Caucasian patients with PCOS or hirsutism as referral diagnosis. Eur J Obstet Gynecol Reprod Biol 2012;163:39-42.
41
42. Bassiouny YA, Rabie WA, Hassan AA, Darwish RK. Association of the luteinizing hormone/choriogonadotropin receptor gene polymorphism with polycystic ovary syndrome. Gynecological Endocrinol 2014;30:428-430.
42
43. Thathapudi S, Kodati V, Erukkambattu J, Addepally U, Qurratulain H. Association of luteinizing hormone chorionic gonadotropin receptor gene polymorphism (rs2293275) with polycystic ovarian syndrome. Genet Test Mol Biomarkers 2015;19:128-132.
43
44. Chen D-J, Ding R, Cao J-Y, Zhai J-X, Zhang J-X, Ye D-Q. Two follicle-stimulating hormone receptor polymorphisms and polycystic ovary syndrome risk: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2014;182:27-32.
44
45. Kambalachenu H, Durairaj Paul S, Nellepalli S, Venkatachalam P. Study on follicle stimulating hormone receptor gene polymorphism in South Indian women with polycystic ovarian syndrome. Am J Med 2013;4:160-167.
45
46. Saxena R, Georgopoulos N, Braaten T, Bjonnes A, Koika V, Panidis D, et al. Han Chinese polycystic ovary syndrome risk variants in women of European ancestry: relationship to FSH levels and glucose tolerance. Hum Reprod 2015;30:1454-1459.
46
47. Abdel-Aziz A, El-Sokkary A, El-Refaeey A, El-Sokkary M, Osman H, El-Saeed RA. Association between follicle stimulating hormone receptor (FSHR) polymorphism and polycystic ovary syndrome among Egyptian women. Int J Biochem Res Rev 2015;5:198-206.
47
48. Qiu L, Liu J, Hei Q-m. Association between two polymorphisms of follicle stimulating hormone receptor gene and susceptibility to polycystic ovary syndrome: a meta-analysis. Chin Med Sci J 2015;30:44-50.
48
49. Jones M, Wilson S, Mullin B, Mead R, Watts G, Stuckey B. Polymorphism of the follistatin gene in polycystic ovary syndrome. Mol Human Reprod 2007;13:237-241.
49
50. Tucci S, Futterweit W, Concepcion ES, Greenberg DA, Villanueva R, Davies TF, et al. Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. J Clin Endocrinol Metab 2001;86:446-449.
50
51. Dasgupta S, Pisapati S, Kudugunti N, Kathragadda A, Godi S, Reddy M. Does follistatin gene have any direct role in the manifestation of polycystic ovary syndrome in Indian women? J Postgrad Med 2012;58:190-193.
51
52. Wang B, Zhou S, Wang J, Liu J, Ni F, Yan J, et al. Identification of novel missense mutations of GDF9 in Chinese women with polycystic ovary syndrome. Reprod Biomed Online 2010;21:344-348.
52
53. Kaiser UB. GnRH receptor signalling. Endocr Abst 2012;29 S25.21.
53
54. Cohen DP, Stein EM, Li Z, Matulis CK, Ehrmann DA, Layman LC. Molecular analysis of the gonadotropin-releasing hormone receptor in patients with polycystic ovary syndrome. Fertil Steril 1999;72:360-363.
54
55. Barzegar MH, Khazali H, Kalantar SM, Khoradmehr A. Effect of Citrullus colocynthis hydro-alcoholic extract on hormonal and folliculogenesis process in estradiol valerate-induced PCOS rat model: An experimental study. Int J Reprod Biomed 2017;15:661-668.
55
56. Fan QR, Hendrickson WA. Structure of human follicle-stimulating hormone in complex with its receptor. Nature 2005;433:269-277.
56
57. Meduri G, Bachelot A, Cocca M, Vasseur C, Rodien P, Kuttenn F, et al. Molecular pathology of the FSH receptor: new insights into FSH physiology. Mol Cell Endocrinol 2008;282:130-142.
57
58. Shimoda C, Koh E, Yamamoto K, Matsui F, Sugimoto K, Sin HS, et al. Single nucleotide polymorphism analysis of the folliclestimulating hormone (FSH) receptor in Japanese with male infertility: identification of codon combination with heterozygous variations of the two discrete FSH receptor gene. Endocr J 2009;56:859-865.
58
59. Capalbo A, Sagnella F, Apa R, Fulghesu A, Lanzone A, Morciano A, et al. The 312N variant of the luteinizing hormone/choriogonadotropin receptor gene (LHCGR) confers up to 2· 7‐fold increased risk of polycystic ovary syndrome in a Sardinian population. Clin Endocrinol 2012;77:113-119.
59
60. Sang Q, Zhang S, Zou S, Wang H, Feng R, Li Q, et al. Quantitative analysis of follistatin (FST) promoter methylation in peripheral blood of patients with polycystic ovary syndrome. Reprod Biomed Online 2013;26:157-163.
60
61. Schneyer A, Sidis Y, Xia Y, Saito S, del Re E, Lin HY, et al. Differential actions of follistatin and follistatin-like 3. Mol Cell Endocrinol 2004;225:25-28.
61
62. Phillips DJ, de Kretser DM. Follistatin: a multifunctional regulatory protein. Front Neuroendocrinol 1998;19:287-322.
62
63. Tsutsui K, Saigoh E, Ukena K, Teranishi H, Fujisawa Y, Kikuchi M, et al. A novel avian hypothalamic peptide inhibiting gonadotropin release. Biochem Biophys Res Commun 2000;275:661-667.
63
64. Salehi MS, Tamadon A, Jafarzadeh Shirazi MR, Namavar MR, Zamiri MJ. The role of arginine-phenylalanine-amide-related peptides in mammalian reproduction. Int J Fertil Steril 2015;9:268-276.
64
65. Zhang Y, Li S, Liu Y, Lu D, Chen H, Huang X, et al. Structural diversity of the GnIH/GnIH receptor system in teleost: its involvement in early development and the negative control of LH release. Peptides 2010;31:1034-1043.
65
66. Jafarzadeh Shirazi MR, Pazoohi F, Zamiri MJ, Salehi MS, Namavar MR, Tamadon A, et al. Expression of RFamide-related peptide in the dorsomedial nucleus of hypothalamus during the estrous cycle of rats. Physiol Pharmacol 2013;17:72-79.
66
67. Kriegsfeld LJ, Mei DF, Bentley GE, Ubuka T, Mason AO, Inoue K, et al. Identification and characterization of a gonadotropin-inhibitory system in the brains of mammals. Proc Natl Acad Sci U S A Biol Sci 2006;103:2410-2415.
67
68. Rizwan MZ, Porteous R, Herbison AE, Anderson GM. Cells expressing RFamide-related peptide-1/3, the mammalian gonadotropin-inhibitory hormone orthologs, are not hypophysiotropic neuroendocrine neurons in the rat. Endocrinology 2008;150:1413-1420.
68
69. Clarke IJ, Sari IP, Qi Y, Smith JT, Parkington HC, Ubuka T, et al. Potent action of RFamide-related peptide-3 on pituitary gonadotropes indicative of a hypophysiotropic role in the negative regulation of gonadotropin secretion. Endocrinology 2008;149:5811-5821.
69
70. Jafarzadeh Shirazi M, Zamiri M, Salehi M, Moradi S, Tamadon A, Namavar M, et al. Differential expression of RFamide-related peptide, a mammalian gonadotrophin-inhibitory hormone orthologue, and kisspeptin in the hypothalamus of Abadeh ecotype does during breeding and anoestrous seasons. J Neuroendocrinol 2014;26:186-194.
70
71. Jafarzadeh Shirazi MR, Namavar MR, Tamadon A. Expression of gonadotropin inhibitory hormone in the preoptic area and its relation with phases of estrous cycle of ewe. Physiol Pharmacol 2011;15:90-96.
71
72. Jafarzadeh Shirazi MR, Tamadon A. Intermediary role of kisspeptin in the stimulation of gonadotropin-releasing hormone neurons by estrogen in the preoptic area of sheep brain. Physiol Pharmacol 2010;14:41-47.
72
73. Jafarzadeh Shirazi MR, Tamadon A, Namavar MR. Coexpression of gonadotropin inhibitory hormone with Agouti-related peptide in the neurons of arcuate nucleus of ewe hypothalamus. Physiol Pharmacol 2011;15:201-209.
73
74. Ubuka T, Inoue K, Fukuda Y, Mizuno T, Ukena K, Kriegsfeld LJ, et al. Identification, expression, and physiological functions of Siberian hamster gonadotropin-inhibitory hormone. Endocrinology 2012;153:373-385.
74
75. Ubuka T, Lai H, Kitani M, Suzuuchi A, Pham V, Cadigan PA, et al. Gonadotropin‐inhibitory hormone identification, cDNA cloning, and distribution in rhesus macaque brain. J Comp Neurol 2009;517:841-855.
75
76. Salehi MS, Shirazi MRJ, Zamiri MJ, Pazhoohi F, Namavar MR, Niazi A, et al. Hypothalamic expression of KiSS1 and RFamide-related peptide-3 mRNAs during the estrous cycle of rats. Int J Fertil Steril 2013;6:304-309.
76
77. Asadi Yousefabad SL, Tamadon A, Rahmanifar F, Jafarzadeh Shirazi MR, Sabet Sarvestani F, Tanideh N, et al. Lactation effect on the mRNAs expression of RFRP-3 and KiSS-1 in dorsomedial and arcuate nuclei of the rat hypothalamus. Physiol Pharmacol 2013;17:277-285.
77
78. Jahanara M, Tamadon A, Jafarzadeh Shirazi MR, Rahmanifar F, Sabet Sarvestani F, Tanideh N, et al. Long term malnutrition and mRNAs expression of RFRP-3 and KiSS-1 in hypothalamus of female ovariectomized rats. Physiol Pharmacol 2014;17:370-378.
78
79. Sarvestani FS, Tamadon A, Koohi-Hosseinabadi O, Nezhad SM, Rahmanifar F, Shirazi MRJ, et al. Expression of RFamide-related peptide-3 (RFRP-3) mRNA in dorsomedial hypothalamic nucleus and KiSS-1 mRNA in arcuate nucleus of rat during pregnancy. Int J Fertil Steril 2014;8:333.
79
80. Ayachi S, Simonin F. Involvement of mammalian RF-amide peptides and their receptors in the modulation of nociception in rodents. Front Endocrinol 2014;5:158.-170.
80
81. Nooranizadeh MH, Rahmanifar F, Jafarzadeh Shirazi MR, Ahmadloo S, Shaaban Z, Tamadon A, et al. Enhancement of melanocortin-4 receptor (MC4R) and constancy of kiss1 mRNAs expression in the hypothalamic arcuate nucleus in a model of polycystic ovary syndrome rat. Galen Med J 2018;7:e1070.
81
82. Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2005;62:644-649.
82
83. Marcondes JAM, Hayashida SA, Barcellos CR, Rocha MP, Maciel GA, Baracat EC. Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors. Arq Bras Endocrinol Metabol 2007;51:972-979.
83
84. Petry CJ, Ong KK, Michelmore KF, Artigas S, Wingate DL, Balen AH, et al. Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. Hum Reprod 2005;20:1837-1843.
84
85. Xita N, Tsatsoulis A, Chatzikyriakidou A, Georgiou I. Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. J Clin Endocrinol Metab 2003;88:5976-5980.
85
86. Park J-M, Lee E-J, Ramakrishna S, Cha D-H, Baek K-H. Association study for single nucleotide polymorphisms in the CYP17A1 gene and polycystic ovary syndrome. Int J Mol Med 2008;22:249-254.
86
87. Banerjee U, Dasgupta A, Khan A, Ghosh MK, Roy P, Rout JK, et al. A cross-sectional study to assess any possible linkage of C/T polymorphism in CYP17A1 gene with insulin resistance in non-obese women with polycystic ovarian syndrome. Indian J Med Res 2016;143:739-747.
87
88. Jones MR, Italiano L, Wilson SG, Mullin BH, Mead R, Dudbridge F, et al. Polymorphism in HSD17B6 is associated with key features of polycystic ovary syndrome. Fertil Steril 2006;86:1438-1446.
88
89. Jones MR, Mathur R, Cui J, Guo X, Azziz R, Goodarzi MO. Independent confirmation of association between metabolic phenotypes of polycystic ovary syndrome and variation in the type 6 17β-hydroxysteroid dehydrogenase gene. J Clin Endocrinol Metab 2009;94:5034-5038.
89
90. Zhang X-L, Zhang C-W, Xu P, Liang F-J, Che Y-N, Xia Y-J, et al. SNP rs2470152 in CYP19 is correlated to aromatase activity in Chinese polycystic ovary syndrome patients. Mol Med Rep 2012;5:245-249.
90
91. Gharani N, Waterworth DM, Batty S, White D, Gilling-Smith C, Conway GS, et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997;6:397-402.
91
92. Reddy KR, Deepika M, Supriya K, Latha KP, Rao SL, Rani VU, et al. CYP11A1 microsatellite (tttta) n polymorphism in PCOS women from South India. J Assist Reprod Genet 2014;31:857-863.
92
93. Shan B, Zhou L, Yang S, Yan M, Wang Z, Ouyang Y, et al. Association between polycystic ovary syndrome (PCOS) and CYP11A1 polymorphism in Hainan, China: a case-control study. Int J Clin Experiment Pathol 2016;9:230-236.
93
94. Yu M, Feng R, Sun X, Wang H, Wang H, Sang Q, et al. Polymorphisms of pentanucleotide repeats (tttta) n in the promoter of CYP11A1 and their relationships to polycystic ovary syndrome (PCOS) risk: a meta-analysis. Mol Biol Rep 2014;41:4435-4445.
94
95. Xu P, Zhang X, Xie G, Zhang C, Shen S, Zhang X, et al. The (TTTA) n polymorphism in intron 4 of CYP19 and the polycystic ovary syndrome risk in a Chinese population. Mol Biol Rep 2013;40:5041-5047.
95
96. Gambineri A, Vicennati V, Genghini S, Tomassoni F, Pagotto U, Pasquali R, et al. Genetic variation in 11β-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:2295-2302.
96
97. Li L, Gu Z-P, Bo Q-M, Wang D, Yang X-S, Cai G-H. Association of CYP17A1 gene-34T/C polymorphism with polycystic ovary syndrome in Han Chinese population. Gynecological Endocrinol 2015;31:40-43.
97
98. Lecke SB, Morsch DM, Spritzer PM. CYP19 gene expression in subcutaneous adipose tissue is associated with blood pressure in women with polycystic ovary syndrome. Steroids 2011;76:1383-1388.
98
99. Xita N, Lazaros L, Georgiou I, Tsatsoulis A. CYP19 gene: a genetic modifier of polycystic ovary syndrome phenotype. Fertil Steril 2010;94:250-254.
99
100. Nagarajeshwari C, Unnisa W, Nalini S, Jahan P, M.L.N D, Ranjith R, Rani U. Androgen associated gene polymorphism(s) in women with polycystic ovary syndrome from South Indian population. 12th Royan Congress on Reproductive Biomedicine and 6th Royan Nursing and Midwifery Seminar. 2011;Supplement 1: 0-0 2011-08-23.
100
101. Jin J-L, Sun J, Ge H-J, Cao Y-X, Wu X-K, Liang F-J, et al. Association between CYP19 gene SNP rs2414096 polymorphism and polycystic ovary syndrome in Chinese women. BMC Med Genet 2009;10:139.
101
102. Mutib MT, Hamdan FB, Al-Salihi AR. Effect of CYP19 Gene on Polycystic Ovary Syndrome Phenotype in Iraqi Women. Iraqi J Med Sci 2015;13:272-278.
102
103. Mostafa RA, Al-Sherbeeny MM, Abdelazim IA, Fahmy AA, Farghali MM, Abdel-Fatah MA, et al. Relation between aromatase gene CYP19 variation and hyperandrogenism in polycystic ovary syndrome Egyptian women. J Infertil Reprod Biol 2016;4:1-5.
103
104. Mehdizadeh A, Kalantar SM, Sheikhha MH, Aali BS, Ghanei A. Association of SNP rs. 2414096 CYP19 gene with polycystic ovarian syndrome in Iranian women. Int J Reprod BioMed 2017;15:491-496.
104
105. Diamanti-Kandarakis E, Bartzis MI, Bergiele AT, Tsianateli TC, Kouli CR. Microsatellite polymorphism (tttta) n at− 528 base pairs of gene CYP11α influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil Steril 2000;73:735-741.
105
106. Gaasenbeek M, Powell BL, Sovio U, Haddad L, Gharani N, Bennett A, et al. Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J Clin Endocrinol Metabol 2004;89:2408-2413.
106
107. San Millán JL, Sancho J, Calvo RM, Escobar-Morreale HF. Role of the pentanucleotide (tttta) n polymorphism in the promoter of the CYP11a gene in the pathogenesis of hirsutism. Fertil Steril 2001;75:797-802.
107
108. Wang Y, Wu X, Cao Y, Yi L, Chen J. A microsatellite polymorphism (tttta) n in the promoter of the CYP11a gene in Chinese women with polycystic ovary syndrome. Fertil Steril 2006;86:223-226.
108
109. Li T, Guijin Z. Role of the pentanucleotide (tttta) n polymorphisms of CYP 11α gene in the pathogenesis of hyperandrogenism in chinese women with polycystic ovary syndrome. J Huazhong Univ Sci Technolog Med Sci 2005;25:212-214.
109
110. Lim SK. Polymorphism of CYP17 and CYP11α for polycystic ovary syndrome in a Korean population. Genes Genom 2002;24:343-348.
110
111. Diamanti-Kandarakis E, Bartzis MI, Zapanti ED, Spina GG, Filandra FA, Tsianateli TC, et al. Polymorphism T-->C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril 1999;71:431-435.
111
112. Prapas N, Karkanaki A, Prapas I, Kalogiannidis I, Katsikis I, Panidis D. Genetics of polycystic ovary syndrome. Hippokratia 2009;13:216-223.
112
113. Comim F, Teerds K, Hardy K, Franks S. Increased protein expression of LHCG receptor and 17α-hydroxylase/17-20-lyase in human polycystic ovaries. Hum Reprod 2013;28:3086-3092.
113
114. Blomquist CH. Kinetic analysis of enzymic activities: prediction of multiple forms of 17β-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 1995;55:515-524.
114
115. Doldi N, Grossi D, Destefani A, Gessi A, Ferrari A. Polycystic ovary syndrome: evidence for reduced 3β-hydroxysteroid dehydrogenase gene expression in human luteinizing granulosa cells. Gynecological Endocrinol 2000;14:32-37.
115
116. Carbunaru G, Prasad P, Scoccia B, Shea P, Hopwood N, Ziai F, et al. The hormonal phenotype of nonclassic 3β-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency. J Clin Endocrinol Metab 2004;89:783-794.
116
117. Qin K, Ehrmann DA, Cox N, Refetoff S, Rosenfield RL. Identification of a functional polymorphism of the human type 5 17β-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:270-276.
117
118. Marioli DJ, Saltamavros AD, Vervita V, Koika V, Adonakis G, Decavalas G, et al. Association of the 17-hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) with hyperandrogenemia in polycystic ovary syndrome (PCOS). Fertil Steril 2009;92:648-652.
118
119. Ju R, Wu W, Fei J, Qin Y, Tang Q, Wu D, et al. Association analysis between the polymorphisms of HSD17B5 and HSD17B6 and risk of polycystic ovary syndrome in Chinese population. Europ J Endocrinol 2015;172:227-233.
119
120. Wood JR, Nelson VL, Ho C, Jansen E, Wang CY, Urbanek M, et al. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J Biol Chem 2003;278:26380-26390.
120
121. Hickey T, Chandy A, Norman R. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:161-165.
121
122. Apparao K, Lovely LP, Gui Y, Lininger RA, Lessey BA. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biol Reprod 2002;66:297-304.
122
123. Catteau-Jonard S, Jamin SP, Leclerc A, Gonzalès J, Dewailly D, di Clemente N. Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:4456-4461.
123
124. Baculescu N. The role of androgen receptor activity mediated by the CAG repeat polymorphism in the pathogenesis of PCOS. J Med Life 2013;6:18-25.
124
125. Lin LH, Baracat MC, Maciel GA, Soares JM, Baracat EC. Androgen receptor gene polymorphism and polycystic ovary syndrome. Int J Gynecol Obst 2013;120:115-118.
125
126. Shah NA, Antoine HJ, Pall M, Taylor KD, Azziz R, Goodarzi MO. Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:1939-1945.
126
127. Mifsud A, Ramirez S, Yong E. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J Clin Endocrinol Metabol 2000;85:3484-3488.
127
128. Jääskeläinen J, Korhonen S, Voutilainen R, Hippeläinen M, Heinonen S. Androgen receptor gene CAG length polymorphism in women with polycystic ovary syndrome. Fertil Steril 2005;83:1724-1728.
128
129. Schüring A, Welp A, Gromoll J, Zitzmann M, Sonntag B, Nieschlag E, et al. Role of the CAG repeat polymorphism of the androgen receptor gene in polycystic ovary syndrome (PCOS). Exp Clin Endocrinol Diabetes 2012;120:73-79.
129
130. Ferk P, Teran N, Gersak K. The (TAAAA) n microsatellite polymorphism in the SHBG gene influences serum SHBG levels in women with polycystic ovary syndrome. Hum Reprod 2006;22:1031-1036.
130
131. Ackerman C, Garcia O, Legro R, Dunaif A, Urbanek M. SHBG (TAAAA) n is associated with serum SHBG in a PCOS case-control cohort. Endocr Rev 2011;32:P2-66.03.
131
132. Moran L, Teede H, Noakes M, Clifton PM, Norman R, Wittert G. Sex hormone binding globulin, but not testosterone, is associated with the metabolic syndrome in overweight and obese women with polycystic ovary syndrome. J Endocrinol Invest 2013;36:1004-1010.
132
133. Martínez-García MÁ, Gambineri A, Alpañés M, Sanchón R, Pasquali R, Escobar-Morreale HF. Common variants in the sex hormone-binding globulin gene (SHBG) and polycystic ovary syndrome (PCOS) in Mediterranean women. Hum Reprod 2012;27:3569-3576.
133
134. Kahsar-Miller MD, Conway-Myers BA, Boots LR, Azziz R. Steroidogenic acute regulatory protein (StAR) in the ovaries of healthy women and those with polycystic ovary syndrome. Am J Obstet Gynecol 2001;185:1381-1387.
134
135. Nazouri AS, Khosravifar M, Akhlaghi AA, Shiva M, Afsharian P. No relationship between most polymorphisms of steroidogenic acute regulatory (StAR) gene with polycystic ovarian syndrome. Int J Reprod BioMed 2015;13:771.
135
ORIGINAL_ARTICLE
Worldwide trends in scientific publications on association of gut microbiota with obesity
Objective(s): Recent evidence has shown underlying roles of gut dysbiosis and metabolic endotoxemia in obesity and its complications. Despite the large number of experimental and clinical researches performed on gut microbiota and obesity, no bibliometrics’ study has been conducted so far. We aimed to assess the trend of global scientific publications in the field of gut microbiota and obesity. Materials and Methods: The bibliometrics’ data from January 2000 to April 2017 were retrieved based on Scopus database. The analysis of the publication year, main source, citation, subject area, co-authorship network, and geographical distribution were carried out, accordingly. The data were analyzed using the Scopus analysis tools, SPSS version 15 and Visualizing Scientific Landscapes (VOS) viewer version 1.6.5. Results: Out of 4384 documents that were identified, the United States published the highest number (28.2%), followed by China and United Kingdom. The number of publications showed an increasing trend over the years of which the most productive year was 2016. The leading subject area was medicine. Most of published scientific documents were original articles and the top source was “PLoS One”. The documents were cited totally 153576 times with average citations per article as 35.03, and h-index of 159. Top author in the co-authorship network assessment was “Wang J.” from China. Conclusion: This study could provide practical sources to researchers to find highly cited studies. Moreover, the study could pave the way for researchers to be engaged in studies which potentially lead to more publication in the field.
https://ijbms.mums.ac.ir/article_11874_d2b2828ae2123718489a4fd2d08b121d.pdf
2019-01-01
65
71
10.22038/ijbms.2018.30203.7281
Bibliometrics
Endotoxemia
Gut flora
Gut microbiota
Obesity
Hanieh-Sadat
Ejtahed
haniejtahed@yahoo.com
1
Obesity and Eating Habits Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Ozra
Tabatabaei-Malazy
tabatabaeiml@sina.tums.ac.ir
2
Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Ahmad-Reza
Soroush
soroush1344@gmail.com
3
Obesity and Eating Habits Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Shirin
Hasani-Ranjbar
shirinhasanir@yahoo.com
4
Obesity and Eating Habits Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Seyed Davar
Siadat
d.siadat@gmail.com
5
Department of Mycobacteriology and Pulmonary Research, Microbiology Research Center, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Jeroen
Raes
jeroen.raes@kuleuven.vib.be
6
Department of Microbiology and Immunology, Rega Institute, KU Leuven, Leuven, Belgium
AUTHOR
Bagher
Larijani
larijanib@tums.ac.ir
7
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
1. Jafari-Adli S, Jouyandeh Z, Qorbani M, Soroush A, Larijani B, Hasani-Ranjbar S. Prevalence of obesity and overweight in adults and children in Iran; a systematic review. J Diabetes Metab Disord 2014;13:121.
1
2. Tabatabaei-Malazy O, Khodaeian M, M.Amoli M. Association between genetic variants and obesity in Iranian population: review article. Iran J Public Health 2014;43:71-82.
2
3. Nguyen DM, El-Serag HB. The epidemiology of obesity. Gastroenterol Clin North Am 2010;39:1-7.
3
4. Segula D. Complications of obesity in adults: a short review of the literature. Malawi Med J 2014;26:20-24.
4
5. Palou A, Bonet ML. Challenges in obesity research. Nutr Hosp 2013;28 Suppl 5:144-153.
5
6. Ejtahed HS, Soroush AR, Angoorani P, Larijani B, Hasani-Ranjbar S. Gut Microbiota as a target in the pathogenesis of metabolic disorders: a new approach to novel therapeutic agents. Horm Metab Res 2016;48:349-358.
6
7. Homayouni-Rad A, Soroush AR, Khalili L, Norouzi-Panahi L, Kasaie Z, Ejtahed HS. Diabetes Management by Probiotics: Current knowledge and future pespective. Int J Vitam Nutr Res 2017:1-13.
7
8. Kvit KB, Kharchenko NV. Gut microbiota changes as a risk factor for obesity. Wiad Lek 2017;70:231-235.
8
9. Dore J, Multon MC, Behier JM. The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect? Therapie 2017;72:21-38.
9
10. Dahiya DK, Renuka, Puniya M, Shandilya UK, Dhewa T, Kumar N, et al. Gut microbiota modulation and its relationship with obesity using prebiotic fibers and probiotics: A review. Front Microbiol 2017;8:563.
10
11. Tabatabaei-Malazy O, Atlasi R, Larijani B, Abdollahi M. Trends in publication on evidence-based antioxidative herbal medicines in management of diabetic nephropathy. J Diabetes Metab Disord 2015;15:1-8.
11
12. Tabatabaei-Malazy O, Ramezani A, Atlasi R, Larijani B, Abdollahi M. Scientometric study of academic publications on antioxidative herbal medicines in type 2 diabetes mellitus. J Diabetes Metab Disord 2016;15:48.
12
13. Bar-Ilan J. Citations to the “Introduction to informetrics” indexed by WOS, Scopus and Google Scholar. Scientometrics 2010;82:495-506.
13
14. Garfield E. The history and meaning of the journal impact factor. JAMA 2006;295:90-93.
14
15. Saha S, Saint S, Christakis DA. Impact factor: a valid measure of journal quality? J Med Libr Assoc 2003;91:42-46.
15
16. Baldock C, Ma R, Orton CG. Point/counterpoint. The h index is the best measure of a scientist’s research productivity. Med Phys 2009;36:1043-1045.
16
17. Van Eck NJ, Waltman L. Text mining and visualization using VOSviewer. Int Soc Scientometr Informetr Newslett 2011;7:50-54.
17
18. Falagas ME, Kouranos VD, Arencibia-Jorge R, Karageorgopoulos DE. Comparison of SCImago journal rank indicator with journal impact factor. FASEB J 2008;22:2623-2628.
18
19. Philippe Mongeon, Ade`le Paul-Hus. The journal coverage of Web of Science and Scopus: a comparative analysis. Scientometrics 2016;106:213-228.
19
20. Kulkarni AV, Aziz B, Shams I, Busse JW. Comparisons of citations in Web of Science, Scopus, and Google Scholar for articles published in general medical journals. JAMA 2009;302:1092-1096.
20
21. Proctor LM. The human microbiome project in 2011 and beyond. Cell Host Microbe 2011;10:287-291.
21
22. Human Microbiome Project Consortium. A framework for human microbiome research. Nature 2012;486:215-221.
22
23. Robles-Alonso V, Guarner F. From basic to applied research: lessons from the human microbiome projects. J Clin Gastroenterol 2014;48 Suppl 1:S3-4.
23
24. Blanco-Miguez A, Gutierrez-Jacome A, Fdez-Riverola F, Lourenco A, Sanchez B. MAHMI database: a comprehensive MetaHit-based resource for the study of the mechanism of action of the human microbiota. Database 2017;2017.
24
25. Dusko Ehrlich S. [Metagenomics of the intestinal microbiota: potential applications]. Gastroenterol Clin Biol 2010;34 Suppl 1:S23-S28.
25
26. Finotello F, Mastrorilli E, Di Camillo B. Measuring the diversity of the human microbiota with targeted next-generation sequencing. Brief Bioinform 2018;19:679-692.
26
27. Ji B, Nielsen J. From next-generation sequencing to systematic modeling of the gut microbiome. Front Genet 2015;6:219-227.
27
28. Rogers GB, Bruce KD. Next-generation sequencing in the analysis of human microbiota: essential considerations for clinical application. Mol Diagn Ther 2010;14:343-350.
28
29. Ejtahed HS, Hasani-Ranjbar S, Larijani B. Human Microbiome as an approach to personalized medicine. Altern Ther Health Med 2017; 23:8-9.
29
30. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-1031.
30
31. Newman ME. The structure of scientific collaboration networks. Proc Natl Acad Sci U S A 2001;98:404-409.
31
ORIGINAL_ARTICLE
Organ toxicity attenuation by nanomicelles containing curcuminoids: Comparing the protective effects on tissues oxidative damage induced by diazinon
Objective(s): Diazinon (DZ) is an organophosphate pesticide that induces oxidative damage in different organs. The aim of this study was to compare the effectiveness of nanomicelles containing curcuminoids (NCUR) and natural curcumin (CUR) in attenuating the oxidative damage induced by DZ in male rats. Materials and Methods: After a single intraperitoneal (IP) injection of DZ (100 mg/kg), the rats were administered either CUR or NCUR (25 and 60 mg/kg, IP). Biomarkers of cell damage including, alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), creatinine (Cr), urea, lactate dehydrogenase (LDH), creatine kinase-MB isoenzyme (CK-MB) and troponin I, were quantified in the serum. Lipid peroxidation (LPO) and glutathione (GSH) content in the liver, kidney, and heart tissues were determined. Results: DZ administration increased the serum levels of ALT, AST, ALP, Cr, urea, LDH, CK-MB, and troponin I; however, the levels significantly (P<0.001) decreased in the CUR- and NCUR-treated groups compared to those in the DZ group. NCUR significantly decreased LPO (P<0.05) and increased GSH (P<0.05) in the heart, kidney, and liver tissues at all doses (especially, at 60 mg/kg) compared with CURConclusion: Our findings suggest that NCUR treatment counters DZ-induced oxidative tissue damage to a greater extent than CUR.
https://ijbms.mums.ac.ir/article_11789_b9e859a8af777f151fd8b5e234e59af4.pdf
2019-01-01
17
24
10.22038/ijbms.2018.23229.5874
Antioxidant
Curcumin
Diazinon
Nanocurcumin
Oxidative stress
Mohammadreza
Abdollahzadeh Estakhri
ma_estakhri@yahoo.com
1
Pharmaceutical Sciences Research Center, Faculty of Pharmacy and Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran
AUTHOR
Mohammad
Shokrzadeh
mslamuk@yahoo.com
2
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
AUTHOR
Mahmoud Reza
Jaafari
jafarimr@mums.ac.ir
3
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
mohammad
karami
toxkarami@gmail.com
4
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
AUTHOR
Hamidreza
Mohammadi
hmohammadi@farabi.tums.ac.ir
5
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
LEAD_AUTHOR
1. Shiri M, Navaei-Nigjeh M, Baeeri M, Rahimifard M, Mahboudi H, Shahverdi AR, et al. Blockage of both the extrinsic and intrinsic pathways of diazinon-induced apoptosis in PaTu cells by magnesium oxide and selenium nanoparticles. Int J Nanotechnol Nanomed 2016; 11:6239.
1
2. Aggarwal V, Deng X, Tuli A, Goh KS. Diazinon—chemistry and environmental fate: A california perspective. Rev Environ Contam Toxicol 2013; 223: 107-140.
2
3. Abdou H, El Mazoudy R. Oxidative damage, hyperlipidemia and histological alterations of cardiac and skeletal muscles induced by different doses of diazinon in female rats. J Hazard Mater 2010; 182:273-278.
3
4. Boussabbeh M, Salem IB, Hamdi M, Fradj SB, Abid-Essefi S, Bacha H. Diazinon, an organophosphate pesticide, induces oxidative stress and genotoxicity in cells deriving from large intestine. Environ Sci Pollut Res 2016; 23:2882-2889.
4
5. Sargazi Z, Nikravesh MR, Jalali M, Sadeghnia HR, Rahimi Anbarkeh F, Mohammadzadeh L. Diazinon-induced ovarian toxicity and protection by vitamins E. Iran J Toxicol 2014; 8:1130-1135.
5
6. Soltaninejad K, Abdollahi M. Current opinion on the science of organophosphate pesticides and toxic stress: a systematic review. Med Sci Monit 2009; 15:RA75-RA90.
6
7. Aluigi M, Guida C, Falugi C. Apoptosis as a specific biomarker of diazinon toxicity in NTera2-D1 cells. Chem Biol Interact 2010; 187:299-303.
7
8.Shah MD, Iqbal M. Diazinon-induced oxidative stress and renal dysfunction in rats. Food Chem Toxicol 2010; 48:3345-3353.
8
9.Jafari M, Salehi M, Ahmadi S, Asgari A, Abasnezhad M, Hajigholamali M. The role of oxidative stress in diazinon-induced tissues toxicity in Wistar and Norway rats. Toxicol Mech Methods 2012; 22:638-647.
9
10.Akturk O, Demirin H, Sutcu R, Yilmaz N, Koylu H, Altuntas I. The effects of diazinon on lipid peroxidation and antioxidant enzymes in rat heart and ameliorating role of vitamin E and vitamin C. Cell Biol Toxicol 2006; 22:455-461.
10
11.Krieger R. Handbook of pesticide toxicology, two-volume set: principles and agents: Academic Press; 2001.
11
12.Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Medica 1991; 57:1-7.
12
13.Calabrese V, Bates TE, Mancuso C, Cornelius C, Ventimiglia B, Cambria MT, et al. Curcumin and the cellular stress response in free radical‐related diseases. Mol Nutr Food Res 2008; 52:1062-1073.
13
14.Soltani B, Ghaemi N, Sadeghizadeh M, Najafi F. Curcumin confers protection to irradiated THP-1 cells while its nanoformulation sensitizes these cells via apoptosis induction. Cell Biol Toxicol 2016; 32:543-561.
14
15.Pandeya N. Old wives’ tales: modern miracles—turmeric as traditional medicine in India. Trees Life J 2005; 1.
15
16.He Y, Yue Y, Zheng X, Zhang K, Chen S, Du Z. Curcumin, inflammation, and chronic diseases: how are they linked? Molecules 2015; 20:9183-9213.
16
17.Hatcher H, Planalp R, Cho J, Torti F, Torti S. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008; 65:1631-1652.
17
18.Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4:807-818.
18
19.Ghalandarlaki N, Alizadeh AM, Ashkani-Esfahani S. Nanotechnology-applied curcumin for different diseases therapy. Biomed Res Int 2014; 2014.
19
20.Shaikh J, Ankola D, Beniwal V, Singh D, Kumar MR. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 2009; 37:223-230.
20
21.Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat 2014; 46:2-18.
21
22.Messarah M, Amamra W, Boumendjel A, Barkat L, Bouasla I, Abdennour C, et al. Ameliorating effects of curcumin and vitamin E on diazinon-induced oxidative damage in rat liver and erythrocytes. Toxicol Ind Health 2013; 29:77-88.
22
23.Jaafari MR. Formulation and preparation of nanomicelles containing curcuminoids for oral use. Iranian Patent Number 83515 2014.
23
24. Rahimi HR, Mohammadpour AH, Dastani M, Jaafari MR, Abnous K, Mobarhan MG, et al. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna J Phytomed 2016; 6:567-577.
24
25.Akinyemi AJ, Onyebueke N, Faboya OA, Onikanni SA, Fadaka A, Olayide I. Curcumin inhibits adenosine deaminase and arginase activities in cadmium-induced renal toxicity in rat kidney. J Food Drug Anal 2017; 25:438-446.
25
26. Sak ME, Soydinc HE, Sak S, Evsen MS, Alabalik U, Akdemir F, et al. The protective effect of curcumin on ischemia-reperfusion injury in rat ovary. Int J Surg 2013; 11:967-970.
26
27. Akinyemi AJ, Oboh G, Fadaka AO, Olatunji BP, Akomolafe S. Curcumin administration suppress acetylcholinesterase gene expression in cadmium treated rats. Neurotoxicology 2017; 62:75-79.
27
28. Katsumaro T, Tohru H. Diazinon concentrations and blood cholinesterase activities in rats exposed to diazinon. Toxicol Lett 1985; 25:7-10.
28
29. Izadi F, Jafari M, Bahdoran H, Asgari A, Divsalar A, Salehi M. The role of N-acetyl cysteine on reduction of diazinon-induced oxidative stress in rat liver and kidney. J Rafsanjan Univ Med Sci 2014; 12:895-906.
29
30. Fernandez F, Goudable C, Sie P, Ton‐That H, Durand D, Suc J, et al. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 1985; 59:139-148.
30
31. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta Gen Subj 1979; 582:67-78.
31
32. Barzegar A. The role of electron-transfer and H-atom donation on the superb antioxidant activity and free radical reaction of curcumin. Food Chem 2012; 135:1369-1376.
32
33. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009; 361:1475-1485.
33
34. Tiwari H, Rao MV. Curcumin supplementation protects from genotoxic effects of arsenic and fluoride. Food Chem Toxicol 2010; 48:1234-1238.
34
35. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D’Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 2005; 224:53-65.
35
36. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today 2012; 17:71-80.
36
37. Yadav A, Lomash V, Samim M, Flora SJ. Curcumin encapsulated in chitosan nanoparticles: a novel strategy for the treatment of arsenic toxicity. Chem Biol Interact 2012; 199:49-61.
37
38. Srinivasan M, Prasad NR, Menon VP. Protective effect of curcumin on γ-radiation induced DNA damage and lipid peroxidation in cultured human lymphocytes. Mutat Res Genet Toxicol Environ Mutagen. 2006; 611:96-103.
38
39. Sonkaew P, Sane A, Suppakul P. Antioxidant activities of curcumin and ascorbyl dipalmitate nanoparticles and their activities after incorporation into cellulose-based packaging films. J Agric Food Chem 2012; 60:5388-5399.
39
40. Alp H, Aytekin I, Esen H, Basarali K, Kul S. Effects of caffeic acid phenethyl ester, ellagic acid, sulforaphane and curcumin on diazinon induced damage to the lungs, liver and kidneys in an acute toxicity rat model. Kafkas Univ Vet Fak Derg 2011; 17:927-933.
40
41. El-Shenawy NS, El-Salmy F, Al-Eisa RA, El-Ahmary B. Amelioratory effect of vitamin E on organophosphorus insecticide diazinon-induced oxidative stress in mice liver. Pestic Biochem Physiol 2010; 96:101-107.
41
42. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicol 2008; 245:194-205.
42
43. Oruç EÖ, Usta D. Evaluation of oxidative stress responses and neurotoxicity potential of diazinon in different tissues of Cyprinus carpio. Environ Toxicol Pharmacol 2007; 23:48-55.
43
44. Isik I, Celik I. Acute effects of methyl parathion and diazinon as inducers for oxidative stress on certain biomarkers in various tissues of rainbowtrout (Oncorhynchus mykiss). Pestic Biochem Physiol 2008; 92:38-42.
44
45. Priscilla DH, Prince PSM. Cardioprotective effect of gallic acid on cardiac troponin-T, cardiac marker enzymes, lipid peroxidation products and antioxidants in experimentally induced myocardial infarction in Wistar rats. Chem Biol Interact 2009; 179:118-124.
45
46. Hariri AT, Moallem SA, Mahmoudi M, Memar B, Hosseinzadeh H. Sub-acute effects of diazinon on biochemical indices and specific biomarkers in rats: protective effects of crocin and safranal. Food Chem Toxicol 2010; 48:2803-2808.
46
47. Kose A, Gunay N, Yildirim C, Tarakcioglu M, Sari I, Demiryurek AT. Cardiac damage in acute organophosphate poisoning in rats: Effects of atropine and pralidoxime. Am J Emerg Med 2009; 27:169-175.
47
48. Tirkey N, Kaur G, Vij G, Chopra K. Curcumin, a diferuloylmethane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys. BMC Pharmacol 2005; 5:1-10.
48
49. Singh RP, Sharad S, Kapur S. Free radicals and oxidative stress in neurodegenerative diseases: relevance of dietary antioxidants. J Indian Acad Clin Med 2004; 5:218-225.
49
50. Kumar A, Dogra S, Prakash A. Protective effect of curcumin (Curcuma longa), against aluminum toxicity: Possible behavioral and biochemical alterations in rats. Behav Brain Res 2009; 205:384-390.
50
51. Rao M. Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol 1997; 49:105-107.
51
52. Somparn P, Phisalaphong C, Nakornchai S, Unchern S, Morales NP. Comparative antioxidant activities of curcumin and its dimethoxy and hydrogenated derivatives. Biol Pharm Bull 2007; 30:74-78.
52
53. Ramawat KG, Dass S, Mathur M. Herbal drugs: ethnomedicine to modern medicine: Springer; 2009.
53
ORIGINAL_ARTICLE
The therapeutic effect of ozonated olive oil plus glucantime on human cutaneous leishmaniasis
Objective(s): Leishmaniasis is one of the main health problems in developing countries, caused by intracellular protozoan parasites of the Leishmania genus. Although research has been successful in discovering vaccines and anti-parasitic drugs like antimony compounds, their side effects like high toxicity, prolonged regeneration, etc., have raised the replacement importance of natural products with antioxidant and antibacterial properties. It can be said that an appropriate alternative to this is the ozonated olive oil. Ozone by introducing O2 in involved tissues and bloodstream could degrade parasite amastigotes and lead to cleared leishmaniasis infections. So, the present study aimed to evaluate the effect of ozonated olive oil in Iranian leishmaniasis patients compared to glucantime, a choice drug for the treatment of Leishmaniasis.Materials and Methods: Thirty patients with confirmed leishmaniasis lesions were included and divided into two groups, 15 cases as control and 15 cases as test with lesions of 30–50 mm2 in diameter. The control group received glucantime intralesionally and the test group ozonated olive oil plus glucantime, 2 times daily.Results: The mean of lesion size was (50.94±33.20) before and (15±14.34) after treatment in control (P<0.00) and (50.88±31.74) before and (9.93±14.18) after treatment in the test group (P<0.00). Moreover, the mean course of therapy was 10.4(±1.84) weeks and 8.93(±2.15) weeks in control and test groups, respectively (P=0.636). Significant differences were reported in lesion size after treatment between the two groups (P<0.00).Conclusion: Data suggested ozonated olive oil can have synergistic effects with glucantime in the treatment of cutaneous leishmaniasis.
https://ijbms.mums.ac.ir/article_11762_0d17e4e4fb53549cbf8fe94088a870fe.pdf
2019-01-01
25
30
10.22038/ijbms.2018.29232.7064
Amastigote
Antimony compounds
Cutaneous Leishmaniasis
Glucantime
Ozonated Olive Oil
Maryam
Aghaei
maryam.aghaei2008@gmail.com
1
Skin Diseases and Leishmaniasis Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Shahrzad
Aghaei
shahrzadaghaei2011@gmail.com
2
Department of Molecular Medicine, School of Advanced Technologies,Shahrekord University of Medical Sciences, Shahrekord, Iran
AUTHOR
Fatemeh
Sokhanvari
dr_sokhanvari@yahoo.com
3
Skin Diseases and Leishmaniasis Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Nazli
Ansari
nazli_ansari@yahoo.com
4
Skin Diseases and Leishmaniasis Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Sayed Mohsen
Hosseini
hosseini66@gmail.com
5
Department of Biostatistics & Epidemiology, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Mohammad Ali
Mohaghegh
mohaghegh1982@yahoo.com
6
Department of Laboratory Sciences, School of Paramedical Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
AUTHOR
Hossein
Hejazi
hejazih12@gmail.com
7
Skin Diseases and Leishmaniasis Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran
LEAD_AUTHOR
1. Bates PA. Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies. Int J Parasitol 2007; 37: 1097-1106.
1
2. Fata A, Salehi G, Rafatpanah H, Mousavi bazzaz M, Mohaghegh MA, Movahedi A. Identification of Leishmania species by kinetoplast DNA-polymerase chain reaction for the first time in Khaf district, Khorasan-e-Razavi province, Iran. Trop Parasitol 2015; 5: 50-54.
2
3. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001; 95: 239-243.
3
4. David CV, Craft N. Cutaneous and mucocutaneous leishmaniasis. Dermatolo Ther 2009; 22: 491-502.
4
5. Hashemi N, Mohaghegh M, Hashemi M, Azami M, Mortazavidehkordi N, Hashemi C, et al. PCR-RFLP diagnosis and characterization of Leishmania species causing human cutaneous leishmaniasis and evaluation of treatment times with glucantime in these patients. Trop Biomed 2016; 33: 689-696.
5
6. Mirzaei F, Bafghi AF, Mohaghegh MA, Jaliani HZ, Faridnia R, Kalani H. In vitro anti-leishmanial activity of Satureja hortensis and Artemisia dracunculus extracts on Leishmania major promastigotes. J Parasit Dis 2016; 40: 1571-1574.
6
7. Pulvertaft RJ, Hoyle GF. Stages in the life-cycle of Leishmania donovani. Trans R Soc Trop Med Hyg 1960; 54: 191-196.
7
8. Machowetz A, Poulsen HE, Gruendel S, Weimann A, Fito M, Marrugat J, et al. Effect of olive oils on biomarkers of oxidative DNA stress in Northern and Southern Europeans. FASEB J 2007; 21: 45-52.
8
9. Al-Waili NS. Mixture of honey, beeswax and olive oil inhibits growth of Staphylococcus aureus and Candida albicans. Arch Med Res 2005; 36: 10-13.
9
10. Perona JS, Arcemis C, Ruiz-Gutierrez V, Catala A. Effect of dietary high-oleic-acid oils that are rich in antioxidants on microsomal lipid peroxidation in rats. J Agric Food Chem 2005; 53: 730-735.
10
11. Rodriguez-Rodriguez R, Herrera MD, Perona JS, Ruiz-Gutierrez V. Potential vasorelaxant effects of oleanolic acid and erythrodiol, two triterpenoids contained in ‘orujo’ olive oil, on rat aorta. Br J Nutr 2004; 92: 635-642.
11
12. Marquez-Martin A, De La Puerta R, Fernandez-Arche A, Ruiz-Gutierrez V, Yaqoob P. Modulation of cytokine secretion by pentacyclic triterpenes from olive pomace oil in human mononuclear cells. Cytokine 2006; 36: 211-217.
12
13. Fernandez-Arche A, Marquez-Martin A, de la Puerta Vazquez R, Perona JS, Terencio C, Perez-Camino C, et al. Long-chain fatty alcohols from pomace olive oil modulate the release of proinflammatory mediators. J Nutr Biochem 2009; 20: 155-162.
13
14. Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. N Engl J Med 1996; 334: 1642-1648.
14
15. Rennecker JL, Mariñas BJ, Owens JH, Rice EW. Inactivation of Cryptosporidium parvum oocysts with ozone. Water Res 1999; 33: 2481-2488.
15
16. Carvajal G, Branch A, Michel P, Sisson SA, Roser DJ, Drewes JE, et al. Robust evaluation of performance monitoring options for ozone disinfection in water recycling using Bayesian analysis. Water Res 2017; 124: 605-617.
16
17. Mandhare M, Jagdale D, Gaikwad P, Gandhi P, Kadam V. Miracle of ozone therapy as an alternative medicine. Int J Pharm Chem Biol Sci 2012; 2: 63-71.
17
18. Elvis AM, Ekta JS. Ozone therapy: A clinical review. J Nat Sci Biol Med 2011; 2: 66-70.
18
19. Torrentino-Madamet M, Almeras L, Desplans J, Le Priol Y, Belghazi M, Pophillat M, et al. Global response of Plasmodium falciparum to hyperoxia: a combined transcriptomic and proteomic approach. Malar J 2011; 10: 4.
19
20. Wickramanayake GB, Rubin AJ, Sproul OJ. Inactivation of Giardia lamblia cysts with ozone. Appl Environ Microbiol 1984; 48: 671-672.
20
21. Casimiro E, Calheiros J, Santos FD, Kovats S. National assessment of human health effects of climate change in Portugal: approach and key findings. Environ Health Perspect 2006; 114: 1950-1956.
21
22. Valacchi G, Bocci V. Studies on the biological effects of ozone: 10. Release of factors from ozonated human platelets. Mediators Inflamm 1999; 8: 205-209.
22
23. Bulynin V, Ermakova A, Glukhov A, Mozhurov I. Wound treatment using the flow of an ozonized solution under high pressure. Khirurgiia 1997: 23-24.
23
24. Gajendrareddy PK, Sen CK, Horan MP, Marucha PT. Hyperbaric oxygen therapy ameliorates stress-impaired dermal wound healing. Brain Behav Immun 2005; 19: 217-222.
24
25. Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol 2003; 81: 355-363.
25
26. Nogales CG, Ferreira MB, Lage-Marques JL. Comparison of the antimicrobial activity of three different concentrations of aqueous ozone on Pseudomonas aeruginosa, Staphylococcus aureus, and Enterococcus faecalis–in vitro study. Revista Española de Ozonoterapia 2014; 4: 9-15.
26
27. Sadatullah S, Mohamed NH, Razak FA. The antimicrobial effect of 0.1 ppm ozonated water on 24-hour plaque microorganisms in situ. Braz Oral Res 2012; 26: 126-131.
27
28. Sechi LA, Lezcano I, Nunez N, Espim M, Dupre I, Pinna A, et al. Antibacterial activity of ozonized sunflower oil (Oleozon). J Appl Microbiol 2001; 90: 279-284.
28
29. Travagli V, Zanardi I, Valacchi G, Bocci V. Ozone and ozonated oils in skin diseases: a review. Mediators Inflamm 2010; 2010: 610418.
29
30. Travagli V, Zanardi I, Bocci V. Topical applications of ozone and ozonated oils as anti-infective agents: an insight into the patent claims. Recent Pat Antiinfect Drug Discov 2009; 4: 130-142.
30
31. Kyriazis JD, Aligiannis N, Polychronopoulos P, Skaltsounis A-L, Dotsika E. Leishmanicidal activity assessment of olive tree extracts. Phytomedicine 2013; 20: 275-281.
31
32. Elamin MH, SS AL-M. Leishmanicidal and apoptotic activities of oleuropein on Leishmania major. Int J Clin Pharmacol Ther 2014; 52: 880-888.
32
33. Velikaya V, Gribova O, Musabaeva L, Startseva Z, Simonov K, Aleinik AN, et al. Ozone therapy for radiation reactions and skin lesions after neutron therapy in patients with malignant tumors. Vopr Onkol 2014; 61: 571-574.
33
34. Rosul MV, Patskan BM. Ozone therapy effectiveness in patients with ulcerous lesions due to diabetes mellitus. Wiad Lek 2016; 69: 7-9.
34
35. Patel PV, Kumar V, Kumar S, Gd V, Patel A. Therapeutic effect of topical ozonated oil on the epithelial healing of palatal wound sites: a planimetrical and cytological study. J Investig Clin Dent 2011; 2: 248-258.
35
36. Rajabi O, Sazgarnia A, Abbasi F, Layegh P. The activity of ozonated olive oil against Leishmania major promastigotes. Iran J Basic Med Sci 2015; 18: 915-919.
36
37. Kim HS, Noh SU, Han YW, Kim KM, Kang H, Kim HO, et al. Therapeutic effects of topical application of ozone on acute cutaneous wound healing. J Korean Med Sci 2009; 24: 368-374.
37
38. Patel PV, Gujjari SK. The morphometrical and histopathological changes which were observed after topical ozone therapy on an exophytic fibrous gingival lesion: A Case Report. J Clin Diagn Res 2013; 7: 1239-1243.
38
39. Kumar T, Arora N, Puri G, Aravinda K, Dixit A, Jatti D. Efficacy of ozonized olive oil in the management of oral lesions and conditions: A clinical trial. Contemp Clin Dent 2016; 7: 51-54.
39
ORIGINAL_ARTICLE
Salidroside regulates the expressions of IL-6 and defensins in LPS-activated intestinal epithelial cells through NF-κB/MAPK and STAT3 pathways
Objective(s): To reveal the detailed mechanism underlying the functions of salidroside on the inflammation of intestinal epithelial cells during IBD.Materials and Methods: Quantitative real-time PCR was employed to assess the expression of IL-6, IL-10, and α-defensins 5 and 6. ELISA assay was performed to measure the secretion of IL-6 and IL-10. MTT assay was used to determine the cell viability and proliferation. Western blot was used to assess the phosphorylation of NF-kB, Erk1/2, JNK, P38, JAK2, and STAT3. Results: Salidroside impaired the proliferation of intestinal epithelial cells at high concentrations (P< 0.05) and down-regulated interleukin-6 (IL-6) production induced by LPS (P<0.05). Western blot results showed that salidroside repressed the phosphorylation of NF-kB, Erk1/2, JNK, P38, JAK2 and STAT3 (P<0.05) and attenuated the activation of NF-κB, MAPK, and STAT3 pathways. Moreover, the expressions of α-defensin 5 and 6 were rescued by salidroside after LPS or SAC triggering (P<0.05). Conclusion: In summary, salidroside suppressed the expression of IL-6 and elevated the expression of defensins in LPS-activated intestinal epithelial cells through NF-κB/MAPK and STAT3 pathways. The mechanism revealed here may be potentially useful for the treatment of IBD with salidroside.
https://ijbms.mums.ac.ir/article_11839_b291d0dd76171e7ed07c9a3c9dbf1bc7.pdf
2019-01-01
31
37
10.22038/ijbms.2018.26994.6602
Defensin
IL-6
Intestinal epithelial cell
MAPK
NF-κB
Salidroside
STAT3
Jiawen
Wang
wangjiawen10086@163.com
1
Department of Anal & Intestinal Disease, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R.China
AUTHOR
Yibin
Pan
panyibin88@163.com
2
Department of Anal & Intestinal Disease, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R.China
AUTHOR
Yongqing
Cao
caoyongqin99@163.com
3
Department of Anal & Intestinal Disease, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R.China
AUTHOR
Wei
Zhou
zhouwei20179@163.com
4
Department of Anal & Intestinal Disease, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R.China
AUTHOR
Jingen
Lu
lujingen2017@163.com
5
Department of Anal & Intestinal Disease, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R.China
LEAD_AUTHOR
Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369:1627-1640.
1
Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. New Engl J Med 2015; 372:1441-1452.
2
Panossian A, Wikman G, Sarris J. Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine 2010; 17:481-493.
3
Song B, Huang G, Xiong Y, Liu J, Xu L, Wang Z, et al. Inhibitory effects of salidroside on nitric oxide and prostaglandin E(2) production in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Med Food 2013; 16:997-1003.
4
Qi Z, Yin F, Lu L, Shen L, Qi S, Lan L, et al. Baicalein reduces lipopolysaccharide-induced inflammation via suppressing JAK/STATs activation and ROS production. Inflamm Res 2013; 62:845-855.
5
Wu YL, Lian LH, Jiang YZ, Nan JX. Hepatoprotective effects of salidroside on fulminant hepatic failure induced by D-galactosamine and lipopolysaccharide in mice. J Pharm Pharmacol 2009; 61:1375-1382.
6
Zhang L, Yu H, Zhao X, Lin X, Tan C, Cao G, et al. Neuroprotective effects of salidroside against beta-amyloid-induced oxidative stress in SH-SY5Y human neuroblastoma cells. Neurochem Int 2010; 57:547-555.
7
Liu Z, Li X, Simoneau AR, Jafari M, Zi X. Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy. Mol Carcinog 2012; 51:257-267.
8
Yan GH, Choi YH. Salidroside attenuates allergic airway inflammation through negative regulation of nuclear factor-kappa B and p38 mitogen-activated protein kinase. J Pharmacol Sci 2014; 126:126-135.
9
Guan S, Feng H, Song B, Guo W, Xiong Y, Huang G, et al. Salidroside attenuates LPS-induced pro-inflammatory cytokine responses and improves survival in murine endotoxemia. Int Immunopharmacol 2011; 11:2194-2199.
10
Wang M, Luo L, Yao L, Wang C, Jiang K, Liu X, et al. Salidroside improves glucose homeostasis in obese mice by repressing inflammation in white adipose tissues and improving leptin sensitivity in hypothalamus. Sci Rep 2016; 6:25399-25412.
11
Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011; 474:298-306.
12
Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol 2014; 14:141-153.
13
Waldner MJ, Neurath MF. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. Semin Immunol 2014; 26:75-79.
14
Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140:1807-1816.
15
Chairatana P, Nolan EM. Defensins, lectins, mucins, and secretory immunoglobulin A: microbe-binding biomolecules that contribute to mucosal immunity in the human gut. Crit Rev Biochem Mol Biol 2017; 52:45-56.
16
Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-[kappa]B as the matchmaker. Nat Immunol 2011; 12:715-723.
17
Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010; 28:573-621.
18
Tak PP, Gerlag DM, Aupperle KR, Van De Geest DA, Overbeek M, Bennett BL, et al. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 2001; 44:1897-1907.
19
Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol 2005; 124:1275-1283.
20
MacMaster JF, Dambach DM, Lee DB, Berry KK, Qiu Y, Zusi FC, et al. An inhibitor of IkappaB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice. Inflamm Res 2003; 52:508-511.
21
Nenci A, Becker C, Wullaert A, Gareus R, van Loo G, Danese S, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2017; 446:557-561.
22
Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 2013; 13:679-692.
23
Mitsuyama K, Suzuki A, Tomiyasu N, Tsuruta O, Kitazaki S, Takeda T, et al. Pro-inflammatory signaling by Jun-N-terminal kinase in inflammatory bowel disease. Int J Mol Med 2006; 17:449-455.
24
Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signalingin inflammatory bowel disease. J Immunol 2002; 168:5342-5351.
25
Medoff BD, Thomas SY, Luster AD. T cell trafficking in allergic asthma: the ins and outs. Annu Rev Immunol 2008; 26:205-232.
26
Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs 2017; 77:521-546.
27
Cenit MC, Alcina A, Márquez A, Mendoza JL, Diaz-Rubio M, de Las Heras V, et al. STAT3 locus in inflammatory bowel disease and multiple sclerosis susceptibility. Genes Immun 2010; 11:264-268.
28
Milner JD, Vogel TP, Forbes L, Ma CA, Stray-Pedersen A, Niemela JE, et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 2015; 125:591-599.
29
Wu D, Yuan P, Ke C, Xiong H, Chen J, Guo J, et al. Salidroside suppresses solar ultraviolet-induced skin inflammation by targeting cyclooxygenase-2. Oncotarget 2016; 7:25971-25982.
30
Gao J, Zhou R, You X, Luo F, He H, Chang X, et al. Salidroside suppresses inflammation in a D-galactose-induced rat model of Alzheimer’s disease via SIRT1/NF-kappaB pathway. Metab Brain Dis 2016; 31:771-778.
31
Qi Z, Qi S, Ling L, Lv J, Feng Z. Salidroside attenuates inflammatory response via suppressing JAK2-STAT3 pathway activation and preventing STAT3 transfer into nucleus. Int Immunopharmacol 2016; 35:265-271.
32
ORIGINAL_ARTICLE
Molecular epidemiology of colistin-resistant Pseudomonas aeruginosa producing NDM-1 from hospitalized patients in Iran
Objective(s): Resistance to carbapenems is the principal reason for the continuing utilization of colistin as a last resort choice for treating the infections resulted from multidrug carbapenem-resistant Pseudomonas aeruginosa (CRPA) isolates. The assessment of antimicrobial resistance pattern, the prevalence of carbapenem-resistance determinants, and molecular epidemiology of colistin-resistant isolates among CRPA strains were the aims of the present research. Materials and Methods: The current cross-sectional research was conducted on 269 CRPA isolates collected from various clinical samples from 2013 to 2016. After performing identification tests, disk diffusion as well as MIC methods were used for testing sensitivity to the antibiotics. Modified Hodge Test (MHT) was utilized to produce carbapenemase. PCR technique identified beta-lactamase classes A, B, and D genes. Results: In total, from 269 CRPA, five isolates (1.3%) were resistant to colistin. It was found that blaNDM-1, blaIMP-1, blaVIM-2, and blaOXA-10 genes were present in 40%, 40%, 20%, and 100% of colistin-resistant isolates, respectively. DLST type 25-11 is a significant cluster of colistin-resistant P. aeruginosa isolates. Conclusion: The appearance of colistin-resistant isolates in CRPA carrying blaNDM-1 with multiple carbapenem-resistant genes shows the great problem in the treatment of P. aeruginosa infections.
https://ijbms.mums.ac.ir/article_11761_7e7144118d9614d327f7ceeb38408565.pdf
2019-01-01
38
42
10.22038/ijbms.2018.29264.7096
Colistin
Double-locus sequence typing
Drug resistance
Pseudomonas aeruginosa
Ahmad
Farajzadeh Sheikh
farajzadehah@gmail.com
1
Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Mojtaba
Shahin
shahin.mojtaba@yahoo.com
2
Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
LEAD_AUTHOR
Leili
Shokoohizadeh
shokoohizadeh@yahoo.com
3
Department of Microbiology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
AUTHOR
Mehrdad
Halaji
mehrdad.md69@gmail.com
4
Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Fereshteh
Shahcheraghi
shahcheraghi@pasteur.ac.ir
5
Department of Bacteriology, Microbiology Research Center, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Fahimeh
Ghanbari
gh.fahimeh63@yahoo.com
6
Student Research Committee, School of Medicine, Shahid Saddoughi University of Medical Sciences, Yazd, Iran
AUTHOR
1. Vaez H, Moghim S, Nasr Esfahani B, Ghasemian Safaei H. Clonal relatedness among imipenem-resistant Pseudomonas aeruginosa isolated from ICU-hospitalized patients. Crit Care Res Pract 2015; 2015.
1
2.Mikucionyte G, Zamorano L, Vitkauskiene A, López-Causapé C, Juan C, Mulet X, et al. Nosocomial dis-semination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania. Eur J Clin Microbiol Infect Dis 2016; 35:195-200.
2
3.Leylabadlo HE, Asgharzadeh M, Aghazadeh M. Dissemination of carbapenemases producing Gram negative bacteria in the Middle East. Iran J Microbiol 2015; 7: 226.
3
4.Merie Queenan A, Bush K. carbapenemases: the versatile B-lactamases. Clin Microbiol Rev 2007; 20: 440-58.
4
5.Jovčić B, Lepšanović Z, Begović J, Filipić B, Kojić M. Two copies of blaNDM-1 gene are present in NDM-1 producing Pseudomonas aeruginosa isolates from Serbia. Antonie van Leeuwenhoek 2014; 105: 613-8.
5
6.Halaji M, Rezaei A, Zalipoor M, Faghri J. Investigation of class I, II, and III Integrons among Acinetobac-ter Baumannii isolates from hospitalized patients in Isfahan, Iran. Oman Med J 2018; 33: 37-42.
6
7.Wei W-J, Yang H-F, Ye Y, Li J-B. New Delhi metallo-β-lactamase-mediated carbapenem resistance: origin, diagnosis, treatment and public health concern. Chin Med J 2015; 128: 1969.
7
8.Lee J-Y, Na IY, Park YK, Ko KS. Genomic variations between colistin-susceptible and-resistant Pseudomo-nas aeruginosa clinical isolates and their effects on colistin resistance. J Antimicrob Chemother 2014; 69: 1248-56.
8
9.Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005; 26: 504-7.
9
10.Dhariwal A, Tullu M. Colistin: Re-emergence of the 'forgotten' antimicrobial agent. J Postgrad Med 2013; 59: 208.
10
11.Goli HR, Nahaei MR, Rezaee MA, Hasani A, Kafil HS, Aghazadeh M. Emergence of colistin resistant Pseu-domonas aeruginosa at Tabriz hospitals, Iran. Iran J Microbiol 2016; 8: 62.
11
12.Basset P, Blanc D. Fast and simple epidemiological typing of Pseudomonas aeruginosa using the double-locus sequence typing (DLST) method. Eur J Clin Microbiol Infect Dis 2014; 33: 927-32
12
13.Cholley P, Stojanov M, Hocquet D, Thouverez M, Bertrand X, Blanc DS. Comparison of double-locus se-quence typing (DLST) and multilocus sequence typing (MLST) for the investigation of Pseudomonas aeruginosa populations. Diagn Microbiol Infect Dis 2015; 82: 274-7
13
14.Luce E. Koneman's color atlas and textbook of diagnostic microbiology. Plast Reconstr Surg 2010; 125: 414-5.
14
15.Lavenir R, Jocktane D, Laurent F, Nazaret S, Cournoyer B. Improved reliability of Pseudomonas aeruginosa PCR detection by the use of the species-specific ecfX gene target. J Microbiol Methods 2007; 70: 20-9.
15
16.Patel J, Cockerill F, Alder J, Bradford P, Eliopoulos G, Hardy D, et al. Performance standards for antimicro-bial susceptibility testing; twenty-fourth informational supplement. CLSI standards for antimicrobial sus-ceptibility testing 2014; 34: 1-226.
16
17.Amjad A, Mirza I, Abbasi S, Farwa U, Malik N, Zia F. Modified Hodge test: A simple and effective test for detection of carbapenemase production. Iran J Microbiol 2011; 3: 189.
17
18.Qu T-t, Zhang J-l, Wang J, Tao J, Yu Y-s, Chen Y-g, et al. Evaluation of phenotypic tests for detection of Metallo-β-lactamase-producing Pseudomonas aeruginosa strains in China. J Clin Microbiol 2009; 47: 1136-42.
18
19.Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis 2011; 70:119-23.
19
20.Pappa O, Beloukas A, Vantarakis A, Mavridou A, Kefala A-M, Galanis A. Molecular characterization and phylogenetic analysis of Pseudomonas aeruginosa isolates recovered from Greek aquatic habitats imple-menting the Double-Locus Sequence Typing Scheme. Microb Ecol 2017; 74: 78-88.
20
21.Shokri D, Khorasgani MR, Fatemi SM, Soleimani-Delfan A. Resistotyping, phenotyping and genotyping of New Delhi metallo-β-lactamase (NDM) among Gram-negative bacilli from Iranian patients. J Med Microbi-ol 2017; 66: 402-11.
21
22.Shanthi M, Sekar U, Kamalanathan A, Sekar B. Detection of New Delhi metallo beta lactamase-1 (NDM-1) carbapenemase in Pseudomonas aeruginosa in a single centre in southern India. Indian J Med Res 2014; 140: 546.
22
23.Mataseje L, Peirano G, Church D, Conly J, Mulvey M, Pitout J. Colistin-nonsusceptible Pseudomonas aeruginosa sequence type 654 with blaNDM-1 arrives in North America. Antimicrob Agents Chemother 2016; 60: 1794-800.
23
24.Saderi H, Owlia P. Detection of multidrug resistant (MDR) and extremely drug resistant (XDR) P. aeruginosa isolated from patients in Tehran, Iran. Iran J Pathol 2015; 10: 265.
24
25. Maroui I, Barguigua A, Aboulkacem A, Ouarrak K, Sbiti M, Louzi H, et al. First report of VIM-2 metallo-β-lactamases producing Pseudomonas aeruginosa isolates in Morocco. J Infect Cemother 2016; 22: 127-32.
25
26.Gill MM, Usman J, Kaleem F, Hassan A, Khalid A, Anjum R, et al. Frequency and antibiogram of multi-drug resistant Pseudomonas aeruginosa. J Coll Physicians Surg Pak 2011; 21: 531-4.
26
27.Bahar MA, Jamali S, Samadikuchaksaraei A. Imipenem-resistant Pseudomonas aeruginosa strains carry metallo-β-lactamase gene bla VIM in a level I Iranian burn hospital. Burns 2010; 36: 826-30.
27
28.Liu P-Y, Weng L-L, Tseng S-Y, Huang C-C, Cheng C-C, Mao Y-C, et al. Colistin resistance of Pseudomonas aeruginosa isolated from snakes in Taiwan. Can J Infect Dis Med Microbiol 2017; 2017.
28
29.Tissot F, Blanc D, Basset P, Zanetti G, Berger M, Que Y-A, et al. New genotyping method discovers sus-tained nosocomial Pseudomonas aeruginosa outbreak in an intensive care burn unit. J Hosp Infect 2016; 94: 2-7.
29
30.Blanc D, Magalhaes BG, Abdelbary M, Prod'hom G, Greub G, Wasserfallen J, et al. Hand soap contamina-tion by Pseudomonas aeruginosa in a tertiary care hospital: no evidence of impact on patients. J Hosp In-fect 2016; 93: 63-7.
30
31.Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg In-fect Dis 2011; 17: 1791.
31
32.Fallah F, Borhan RS, Hashemi A. Detection of bla (IMP) and bla (VIM) metallo-β-lactamases genes among Pseudomonas aeruginosa strains. International . Int J Burns Trauma 2013; 3: 122.
32
33.Golshani Z, Sharifzadeh A. Prevalence of blaOxa10 type beta-lactamase gene in carbapenemase producing Pseudomonas aeruginosa strains isolated from oatients in Isfahan. Jundishapur J Microbiol 2013; 6.
33
ORIGINAL_ARTICLE
Protective effects of celecoxib on ischemia reperfusion–induced acute kidney injury: comparing between male and female rats
Objective(s): There is increasing evidence for the importance of gender in different diseases; however, the role of gender in response to treatments is still unknown. Therefore, this study investigated the impact of gender on the protective effects of celecoxib in ischemia reperfusion (IR)-induced acute kidney injury.Materials and Methods: In this experimental study, rats were randomly divided into 6 groups (n=6): IR, sham and celecoxib groups of males and females. In IR groups, after orally receiving saline for 5 days, renal pedicles were clamped for 55 min and then kidneys were reperfused for 24 hr. In the sham groups, clamping of renal pedicles was not performed. In the celecoxib groups, 30 mg/kg celecoxib was given orally for 5 days before induction of ischemia. Plasma was collected to determine creatinine (Cr) and blood urea nitrogen (BUN). Kidney tissue samples were also stored for examining the histopathology and measuring malondialdehyde (MDA) levels and superoxide dismutase (SOD) activities.Results: IR caused significant increases in plasma Cr (P<0.05), BUN (P<0.05) and renal histopathological damages in both genders. Also, induction of IR resulted in significant increase of MDA levels (P<0.05) and decrease of SOD activities (P<0.05) in the kidney in both genders. Celecoxib administration prevented the IR-induced functional, histopathological and oxidative changes in both genders by similar degrees.Conclusion: This study suggested that in similar pathological conditions, celecoxib improves renal function and histopathological damages and attenuates oxidative stress in both genders by the same degrees. These protective effects of celecoxib on IR-induced kidney injury are gender-independent.
https://ijbms.mums.ac.ir/article_11741_724322512115c9bc2b3555eb6b1f4d0f.pdf
2019-01-01
43
48
10.22038/ijbms.2018.29644.7156
Acute kidney injury
Celecoxib
Gender difference
Oxidative stress
Reperfusion injury
Farzaneh
Kianian
kianian.f1989@gmail.com
1
Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Behjat
Seifi
b-seifi@tums.ac.ir
2
Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Mehri
Kadkhodaee
kadkhodm@tums.ac.ir
3
Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Abdullah
Sajedyzadeh
asajedyzadeh@yahoo.com
4
Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Parisa
Ahghari
p-ahghari@razi.tums.ac.ir
5
Department of Physiology, School of Medicine, Hamedan University of Medical Sciences, Hamedan, Iran
AUTHOR
1. Bolisetty S, Zarjou A, Agarwal A. Heme oxygenase 1 as a therapeutic target in acute kidney injury. Am J Kidney Dis 2017; 69:531-545.
1
2. Makris K, Spanou L. Acute kidney injury: definition, pathophysiology and clinical phenotypes. Clin Biochem Rev 2016; 37:85-98.
2
3. Oliveira R, Brito M, Júnior R, Gonçalves R, Oliveira L, Monteiro A, et al. Influence of remote ischemic conditioning and tramadol hydrochloride on oxidative stress in kidney ischemia/reperfusion injury in rats. Acta Cir Bras 2017; 32:229-235.
3
4. Menting T, Ergun M, Bruintjes M, Wever K, Lomme R, van Goor H, et al. Repeated remote ischemic preconditioning and isoflurane anesthesia in an experimental model of renal ischemia-reperfusion injury. BMC Anesthesiol 2017; 17:1-7.
4
5. Thanan R, Oikawa S, Hiraku Y, Ohnishi S, Ma N, Pinlaor S, et al. Oxidative stress and its significant roles in neurodegenerative diseases and cancer. Int J Mol Sci 2014; 16:193-217.
5
6. Harris RE. Inflammation in the pathogenesis of chronic diseases: the COX-2 controversy: Springer Science & Business Media 2007.
6
7. Alzoghaibi M. Concepts of oxidative stress and antioxidant defense in Crohn’s disease. World J Gastroenterol 2013; 19:6540-6547.
7
8. Gonzalez-Vicente A, Garvin J. Effects of reactive oxygen species on tubular transport along the nephron. Antioxidants 2017; 6:1-15.
8
9. Xu C, Gu K, Yasen Y, Hou Y. Efficacy and safety of celecoxib therapy in osteoarthritis: A meta-analysis of randomized controlled trials. Medicine 2016; 95:e3585.
9
10. Müller V, Losonczy G, Heemann U, Vannay Á, Fekete A, Reusz G, et al. Sexual dimorphism in renal ischemia-reperfusion injury in rats: possible role of endothelin. Kidney Int 2002; 62:1364-1371.
10
11. Azizi F, Seifi B, Kadkhodaee M, Ahghari P. Administration of hydrogen sulfide protects ischemia reperfusion-induced acute kidney injury by reducing the oxidative stress. Ir J Med Sci 2016; 185:649-654.
11
12. Ozturk H, Gezici A, Ozturk H. The effect of celecoxib, a selective COX-2 inhibitor, on liver ischemia/reperfusion-induced oxidative stress in rats. Hepatol Res 2006; 34:76-83.
12
13. Esterbauer H, Schaur R, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11:81-128.
13
14. Paoletti F, Mocali A. Changes in CuZn-superoxide dismutase during induced differentiation of murine erythroleukemia cells. Cancer Res 1988; 48:6674-6677.
14
15. Patel N, Cuzzocrea S, Collino M, Chaterjee P, Mazzon E, Britti D, et al. The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. Eur J Pharmacol 2007; 562:148-154.
15
16. Weinberg J. The cell biology of ischemic renal injury. Kidney Int 1991; 39:476-500.
16
17. Kim J, Jang H, Park K. Reactive oxygen species generated by renal ischemia and reperfusion trigger protection against subsequent renal ischemia and reperfusion injury in mice. Am J Physiol Renal Physiol 2009; 298:F158-F166.
17
18. Shanley P, Rosen M, Brezis M, Silva P, Epstein F, Rosen S. Topography of focal proximal tubular necrosis after ischemia with reflow in the rat kidney. Am J Pathol 1986; 122:462-468.
18
19. Myers B, Miller D, Mehigan J, Olcott C, Golbetz H, Robertson C, et al. Nature of the renal injury following total renal ischemia in man. J Clin Invest 1984; 73:329-341.
19
20. Bonventre J, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011; 121:4210-4221.
20
21. Liu Y, Liu X, Wang L, Du Y, Chen Z, Chen H, et al. Effects of apigenin on the expression levels of B‑cell lymphoma‑2, Fas and Fas ligand in renal ischemia‑reperfusion injury in rats. Exp Ther Med 2017; 14:5345-5354.
21
22. Ebrahimi S, Aboutaleb N, Nobakht M. Consequences of ischemic preconditioning of kidney: comparing between male and female rats. Iran J Basic Med Sci 2012; 15: 1148-1153.
22
23. Hu H, Wang G, Batteux F, Nicco C. Gender differences in the susceptibility to renal ischemia-reperfusion injury in BALB/c mice. Tohoku J Exp Med 2009; 218:325-329.
23
24. Park K, Kim J, Ahn Y, Bonventre A, Bonventre J. Testosterone is responsible for enhanced susceptibility of males to ischemic renal injury. J Biol Chem 2004; 279:52282-52292.
24
25. Suddek G, El-kenawi A, Abdel-Aziz A, El-Kashef H. Celecoxib, a selective cyclooxygenase-2 inhibitor, attenuates renal injury in a rat model of cisplatin-induced nephrotoxicity. Chemotherapy 2011; 57:321-326.
25
26. Ide T, Tsutsui H, Ohashi N, Hayashidani S, Suematsu N, Tsuchihashi M, et al. Greater oxidative stress in healthy young men compared with premenopausal women. Arterioscler Thromb Vasc Biol 2002; 22:438-442.
26
27. Brandes R, Mügge A. Gender differences in the generation of superoxide anions in the rat aorta. Life Sci 1997; 60:391-396.
27
28. Sapirstein A, Bonventre J. Phospholipases A2 in ischemic and toxic brain injury. Neurochem Res 2000; 25:745-753.
28
29. Ueno N, Takegoshi Y, Kamei D, Kudo I, Murakami M. Coupling between cyclooxygenases and terminal prostanoid synthases. Biochem Biophys Res Commun 2005; 338:70-76.
29
30. Tabassum R, Vaibhav K, Shrivastava P, Khan A, Ahmed M, Ashafaq M, et al. Perillyl alcohol improves functional and histological outcomes against ischemia–reperfusion injury by attenuation of oxidative stress and repression of COX-2, NOS-2 and NF-κB in middle cerebral artery occlusion rats. Eur J Pharmacol 2015; 747:190-199.
30
31. Feitoza C, Câmara N, Pinheiro H, Gonçalves G, Cenedeze M, Pacheco-Silva A, et al. Cyclooxygenase 1 and/or 2 blockade ameliorates the renal tissue damage triggered by ischemia and reperfusion injury. Int Immunopharmacol 2005; 5:79-84.
31
32. Feitoza C, Gonçalves G, Semedo P, Cenedeze M, Pinheiro H, Beraldo F, et al. Inhibition of COX 1 and 2 prior to renal ischemia/reperfusion injury decreases the development of fibrosis. Mol Med 2008; 14: 724-730.
32
33. Mahfoudh-Boussaid A, Zaouali M, Hadj-Ayed K, Miled A, Saidane-Mosbahi D, Rosello-Catafau J, et al. Ischemic preconditioning reduces endoplasmic reticulum stress and upregulates hypoxia inducible factor-1α in ischemic kidney: the role of nitric oxide. J Biomed Sci 2012; 19:1-8.
33
34. Paller M, Hoidal J, Ferris T. Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest 1984; 74:1156-1164.
34
35. Mahmoudi A, Kadkhodaee M, Golab F, Najafi A, Sedaghat Z. Postconditioning is protective in renal reperfusion injury only in male rats. A gender difference study. Physiol Int 2014; 102:67-76.
35
36. Sedaghat Z, Kadkhodaee M, Seifi B, Salehi E, Najafi A, Dargahi L. Remote per‐conditioning reduces oxidative stress, downregulates cyclo‐oxygenase‐2 expression and attenuates ischaemia–reperfusion‐induced acute kidney injury. Clin Exp Pharmacol Physiol 2013; 40:97-103.
36
37. Koul A, Arora N. Celecoxib mitigates cigarette smoke induced oxidative stress in mice. Indian J Biochem Biophys 2010; 47:285-291
37
ORIGINAL_ARTICLE
Effects of citral on oxidative stress and hepatic key enzymes of glucose metabolism in streptozotocin/high-fat-diet induced diabetic dyslipidemic rats
Objective(s): Phytochemicals such as polyphenols, alkaloids, and terpenoids, protect against the development of early stages and complications of diabetes mellitus according to various reports. The aim of this study was to measure the anti-dyslipidemic and anti-diabetic effects of Citral on high-fat-diet (HFD) and streptozotocin (STZ) induced diabetic dyslipidemic rats and to see also its effect on carbohydrate metabolic regulatory enzymes in the liver. Materials and Methods: Rats were kept on a high-fat diet for 2 weeks, then diabetes was induced by a single dose of STZ (35 mg/kg/BW, intraperitoneally), Citral was administered orally at a dose of 45 mg/kg/BW for 28 days to diabetic rats. Blood glucose, plasma insulin, and lipid profile in blood were studied. Antioxidant activities were assayed in the liver, pancreas, and adipose tissues. Carbohydrate metabolic enzymes of the liver were also studied in diabetic dyslipidemic rats.Results: The results of this study confirmed that administration of Citral significantly (P<0.05) decreased the blood glucose level and increased plasma insulin in diabetic rats. Citral also improved oxidative markers along with anti-oxidative enzymes of the liver, adipose tissue, and pancreas in the HFD/STZ group. Citral also regulated the activity of the glucose-metabolic enzymes in the liver. The results of the present study were compared to Glibenclamide, which is a standard oral drug for lowering the blood sugar. Conclusion: Results may show that Citral possesses anti-dyslipidemic activity as well as anti-diabetic activity and also regulates the enzyme activity of glycolytic and gluconeogenic processes in the liver.
https://ijbms.mums.ac.ir/article_11691_3994a2d9f6b44bae36ea9ff9952b35da.pdf
2019-01-01
49
57
10.22038/ijbms.2018.26889.6574
Carbohydrate metabolism
Citral
Diabetes
Dyslipidemia
Enzymes
Oxidative stress
Streptozotocin
Chetna
Mishra
chetnam@iul.ac.in
1
Department of Biochemistry, King George’s Medical University, Lucknow-226003, Uttar Pradesh, India
AUTHOR
Monowar
Khalid
makhalid@iul.ac.in
2
Department of Environmental Science, Integral University, Lucknow-226021, Uttar Pradesh, India
AUTHOR
Naazmin
Fatima
nazftm89@gmail.com
3
Department of Biochemistry, King George’s Medical University, Lucknow-226003, Uttar Pradesh, India Lucknow- 226003, Uttar Pradesh, India
AUTHOR
Babita
Singh
babitasingh1987@rediffmail.com
4
Department of Biochemistry, King George’s Medical University, Lucknow-226003, Uttar Pradesh, India
AUTHOR
Dinesh
Tripathi
dineshtbt2009@gmail.com
5
Department of Physiology, King George’s Medical University, Lucknow- 226003, Uttar Pradesh, India
AUTHOR
Mohammad
Waseem
mdwaseemsayeed@gmail.com
6
Department of Biochemistry, King George’s Medical University, Lucknow-226003, Uttar Pradesh, India
AUTHOR
Abbas Ali
Mahdi
abbasalimahdi15@gmail.com
7
Department of Biochemistry, King George’s Medical University, Lucknow-226003, Uttar Pradesh, India
LEAD_AUTHOR
International Diabetes Federation Website. [(Accessed on 9 May 2016)]. http://www.Idf.Org/media-events/press-releases/2015/diabetes-atlas-7th-edition.
1
Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. The Australas Med J 2014; 7:45-48.
2
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care 2014; 37(Supplement 1):S81-S90.
3
Maritim A, Dene BA, Sanders RA, Watkins JB. Effects of pycnogenol treatment on oxidative stress in streptozotocin‐induced diabetic rats. J Biochem Mol Toxicol 2003; 17:193-199.
4
Ma Q, Guo Y, Sun L, Zhuang Y. Anti-Diabetic Effects of Phenolic Extract from Rambutan Peels (Nephelium lappaceum) in High-Fat Diet and Streptozotocin-Induced Diabetic Mice. Nutrients 2017; 9:801-812.
5
Elberry AA, Harraz FM, Ghareib SA, Gabr SA, Nagy AA, Abdel-Sattar E. Methanolic extract of Marrubium vulgare ameliorates hyperglycemia and dyslipidemia in streptozotocin-induced diabetic rats. Int J Diabetes Mellit 2015; 3:37-44.
6
Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes 2015; 6:456.
7
Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2011; 29:116-122.
8
Watkins PJ. ABC of diabetes: cardiovascular disease, hypertension, and lipids. BMJ 2003; 326:874-876.
9
Sivitz WI. Lipotoxicity and glucotoxicity in type 2 diabetes: effects on development and progression. Postgrad Med 2001; 109:55-64.
10
Ozougwu JC, Obimba KC, Belonwu CD, Unakalamba CB. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. J Physiol Pathophysiol 2013; 4(4):46-57.
11
Wilcox G. Insulin and insulin resistance. Clin Biochemist Rev 2005; 26:19-39.
12
Manvitha K, Bidya B. Review on pharmacological activity of Cymbopogon citratus. Intl J Herbal Med 2014; 1: 5-7.
13
Tiwari M, Dwivedi UN, Kakkar P. Suppression of oxidative stress and pro-inflammatory mediators by Cymbopogon citratus D. Stapf extract in lipopolysaccharide stimulated murine alveolar macrophages. Food Chem Toxicol 2010; 48:2913-2919.
14
Liang CP, Wang M, Simon JE, Ho CT. Antioxidant activity of plant extracts on the inhibition of Citral off‐odor formation. Mol Nutr Food Res 2004; 48:308-317.
15
Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 2005; 52:313-320.
16
Najafian M, Ebrahim-Habibi A, Yaghmaei P, Parivar K, Larijani, B. Citral as a potential antihyperlipidemic medicine in diabetes: a study on streptozotocin-induced diabetic rats. IJDLD 2011; 10: 1- 8.
17
Modak T, Mukhopadhaya A. Effects of Citral, a naturally occurring antiadipogenic molecule, on an energy-intense diet model of obesity. Ind J Pharmacol 2011; 43:300-305.
18
Husain I, Chander R, Saxena JK, Mahdi AA, Mahdi F. Antidyslipidemic effect of Ocimum sanctum leaf extract in streptozotocin induced diabetic rats. Ind J Clin Biochem 2015; 30:72-77.
19
Kapoor R, Kakkar P. Naringenin accords hepatoprotection from streptozotocin induced diabetes in vivo by modulating mitochondrial dysfunction and apoptotic signaling cascade. Toxicol Reports 2014; 1:569-581.
20
Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 1969; 6:24-27.
21
Grassi J, Pradelles P, inventors; Commissariat al’Energie Atomique, assignee. Compound labelled by the acetyl cholinesterase of electrophorus electricus, its preparation process and its use as a tracer or marker in enzymoimmunological determinations. United States patent US 5,047,330. 1991 Sep 10.
22
Goldstein DE, Parker KM, England JD, England JE, Wiedmeyer HM, Rawlings SS, et al. Clinical application of glycosylated hemoglobin measurements. Diabetes 1982; 31(Supplement 3):70-78.
23
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-275.
24
Okada M, Matsui H, Ito Y, Fujiwara A, Inano K. Low-density lipoprotein cholesterol can be chemically measured: a new superior method. J Lab Clin Med 1998; 132(3):195-201.
25
Mosinger F. Photometric adaptation of Dole’s microdetermination of free fatty acids. J lipid Res 196; 6:157-159.
26
Deeg R, Ziegenhorn J. Kinetic enzymic method for automated determination of total cholesterol in serum. Clin Chem 1983; 29:1798-1802.
27
Baginski ES, Epstein E, Zak B. The measurement of serum total phospholipids. Ann Clin Lab Sci 1972; 2:255-267.
28
Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973; 19:476-482.
29
Ohkawa H, Ohishi N. Reaction of thiobarbituric acid with linoleic acid hydroperoxide. J Lipid Res 1978; 19:1053-1057.
30
Reznick AZ, Packer L. Oxidative damage to proteins: Spectrophotometric method for carbonyl assay. Methods Enzymol 1994; 233: 357-363.
31
McCord JM, Fridovich I. Superoxide dismutase an enzymic function for erythrocuprein (hemocuprein). J Biol Chemistry. 1969 Nov 25; 244:6049-6055.
32
Aebi H. Catalase in vitro. Methods Enzymol. 1984; 105:121-126.
33
Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70:158-169.
34
Hazelton GA, Lang CA. Glutathione contents of tissues in the aging mouse. Biochem J 1980; 188:25-30.
35
Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82:70-77.
36
Sharma C, Manjeshwar R, Weinhouse S. Effects of diet and insulin on glucose-adenosine triphosphate phosphotransferases of rat liver. J Biol Chem 1963; 238:3840-3845.
37
Crane RK, Sols A. Animal tissue hexokinases:(Soluble and particulate forms) Hexose+ ATP→ Hexose-6-P+ ADP. Methods Enzymol 1955; 1:277-286.
38
Fiske CH, Subbarow Y. The colorimetric determination of phosphorus. J Biol Chem 1925; 66:375-400.
39
Parks WC, Drake RL. Insulin mediates the stimulation of pyruvate kinase by a dual mechanism. Biochem J 1982; 208:333-337.
40
Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 1988; 115:61-69.
41
Ramesh B, Pugalendi KV. Antihyperglycemic effect of umbelliferone in streptozotocin-diabetic rats. J Med Food 2006; 9:562-566.
42
Jainandunsing S, Ozcan B, Rietveld T, van Miert JN, Isaacs AJ, Langendonk JG, et al. Failing beta-cell adaptation in SouthAsian families with a high risk of type 2 diabetes. Acta Diabetol 2015; 52:11–19
43
Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7:947–953.
44
Sundaram R, Naresh R, Shanthi P, Sachdanandam P. Modulatory effect of green tea extract on hepatic key enzymes of glucose metabolism in streptozotocin and high fat diet induced diabetic rats. Phytomedicine 2013; 20:577-584.
45
Kirana H, Srinivasan BP. Trichosanthes cucumerina Linn. improves glucose tolerance and tissue glycogen in non insulin dependent diabetes mellitus induced rats. Indian J Pharmacol 2008;3:103–106.
46
Raghavan B, Kumari SK. Effect of Terminalia arjuna stem bark on antioxidant status in liver and kidney of alloxan diabetic rats. Ind J Physiol Pharmacol 2006; 50:133.
47
Daisy P, Eliza J, Farook KA. A novel dihydroxy gymnemic triacetate isolated from Gymnema sylvestre possessing normoglycemic and hypolipidemic activity on STZ-induced diabetic rats. J Ethnopharmacol 2009; 126:339-344.
48
Goodarzi MT, Zal F, Malakooti M, Sadeghian MS. Inhibitory activity of flavonoids on the lens aldose reductase of healthy and diabetic rats. Acta Medica Iranica 2006;44:41-45.
49
Parveen K, Khan R, Siddiqui WA. Antidiabetic effects afforded by Terminalia arjuna in high fat-fed and streptozotocin-induced type 2 diabetic rats. Int J Diab Metab 2011; 19:23-33.
50
Yusufoglu HS, Soliman GA, Abdel-Rahman RF, Abdel-Kader MS, Ganaie MA, Bedir E, et al. Antihyperglycemic and antihyperlipidemic effects of Ferula duranii in experimental type 2 diabetic rats. Int J Pharmacol 2015; 11:532-541.
51
Raz I, Eldor R, Cernea S, Shafrir E. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev 2005; 21:3-14.
52
Arvind K, Pradeepa R, Deepa R, Mohan V. Diabetes and coronary artery disease. J Med Res 2002; 116:121-132.
53
Yang H, Li X. The role of fatty acid metabolism and lipotoxicity in pancreatic β-cell injury: identification of potential therapeutic targets. Acta Pharma Sin B 2012; 2:396-402.
54
Suanarunsawat T, Ayutthaya WD, Thirawarapan S, Poungshompoo S. Anti-oxidative, anti-hyperglycemic and lipid-lowering effects of aqueous extracts of Ocimum sanctum L. leaves in diabetic rats. Food Nutr Sci 2014; 5:801-811.
55
Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes 2015; 6:456.
56
Chevion M, Berenshtein E, Stadtman ER. Human studies related to protein oxidation: protein carbonyl content as a marker of damage. Free Rad Res 2000; 33:S99-108.
57
Kumar G, Banu GS, Murugesan AG. Effect of Helicteres isora bark extracts on heart antioxidant status and lipid per oxidation in streptozotocin diabetic rats. J Appl Biomed 2008; 6: 89-95.
58
Ahmed S, Rahman A, Alam A, Saleem M, Athar M, Sultana S. Evaluation of the efficacy of Lawsonia alba in the alleviation of carbon tetrachloride-induced oxidative stress. J Ethnopharmacol 2000; 69:157-164.
59
Grassmann J. Terpenoids as plant antioxidants. Vitam Horm 2005; 72:505-535.
60
Murray RK, Granner DK, Mayes PA, Rodwell VW, Biochemistry HS. Appleton and Lange. Norwalk, CT 1993; 518.
61
Pavana P, Sethupathy S, Manoharan S. Antihyperglycemic and antilipidperoxidative effects of Tephrosia purpurea seed extract in streptozotocin induced diabetic rats. Ind J Clin Biochem 2007; 22:77-83.
62
Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012; 56:952-964.
63
Rathi SS, Grover JK, Vats V. The effect of Momordica charantia and Mucuna pruriens in experimental diabetes and their effect on key metabolic enzymes involved in carbohydrate metabolism. Phyto Res 2002; 16:236-243.
64
Pari L, Suman S. Efficacy of naringin on hepatic enzymes of carbohydrate metabolism in streptozotocin-nicotinamide induced type 2 diabetic rats. Int J Pharm Biol Arch 2010; 1:280-286.
65
Grover JK, Vats V, Rathi SS. Anti-hyperglycemic effect of Eugenia jambolana and Tinospora cordifolia in experimental diabetes and their effects on key metabolic enzymes involved in carbohydrate metabolism. J Ethnopharmacol 2000; 73:461-470.
66
Mithieux G, Rajas F, Gautier-Stein A. A novel role for glucose 6-phosphatase in the small intestine in the control of glucose homeostasis. J Biol Chem 2004; 279:44231-44234.
67
Ragavan B, Krishnakumari S. Antidiabetic effect of T. arjuna bark extract in alloxan induced diabetic rats. Ind J Clin Biochem 2006; 21:123-128.
68
RajeswaraReddy S, Lavany T, Ganapathi Narasimhulu KS. Effect of pimpinellatirupatiensison oxidative enzymes in STZ-induced diabetic rat kidney. Iran J Pharma Res 2012; 11:277-286.
69
Talaiezadeh A, Shahriari A, Tabandeh MR, Fathizadeh P, Mansouri S. Kinetic characterization of lactate dehydrogenase in normal and malignant human breast tissues. Cancer Cell Int 2015; 15:19-27.
70
Ramachandran B, kandaswamy M, Narayanan V, Subramanian S. Insulin mimetic effects of macrocyclic binuclear oxovanadium complexes on streptozotocin-induced experimental diabetes in rats.Diabetes Obes. Metab 2003; 5:455–461.
71
Giribabu N, Eswar KK, Swapna RS, Muniandy S, Salleh N. Vitis vinifera (Muscat Variety) seed ethanolic extract preserves activity levels of enzymes and histology of the liver in adult male rats with diabetes. Evid Based Complement Alternat Med 2015; Article ID 542026: 8 pages.
72
Visweswara Rao P, Madhavi K, Dhananjaya Naidu M, Gan SH. Rhinacanthus nasutus ameliorates cytosolic and mitochondrial enzyme levels in streptozotocin-induced diabetic rats. Evid Based Complement Alternat Med 2013; Article ID 486047:6 pages.
73
ORIGINAL_ARTICLE
Pseudomonas aeruginosa keratitis: passive immunotherapy with antibodies raised against divalent flagellin
Objective(s): Pseudomonas aeruginosa infections such as keratitis are considered among the major health problems worldwide due to the complexity of pathogenesis and antibiotic resistance crisis, thus, finding new effective approaches for prevention and treatment of the infections seem to be still vital. In this report, we aimed to investigate the therapeutic effects of topical administration of the antibodies against type a and b-flagellin (FLA and FLB) in Pseudomonas keratitis model of infection in mice. Materials and Methods: Scratched corneas of mice were treated with approximately 107 CFUs/eye of PAK and/or PAO1 strains of P. aeruginosa. Specific IgG to FLA, FLB or divalent flagellin were topically applied to the infected corneas for 20 min, 24, and 36 hr post-infection. The bacterial burden and myeloperoxidase activity (as a marker for polymorphonuclears (PMNs) infiltration) were determined in the corneas. The biological activity of the anti-FLA and FLB IgG was evaluated in vitro by opsonophagocytosis test. Results: Compared to other treated corneas, divalent anti-flagellin IgG treatment showed a significant decrease in the bacterial CFUs and myeloperoxidase activity in the infected corneas (P<0.05). Results of opsonophagocytosis revealed that the specific antibodies raised against FLA and FLB had more potent opsonic killing activity on their homologous strains as compared with control group (P<0.05). Conclusion: It appears that in P. aeruginosa keratitis, topical administration of the combined antibodies likely via decreasing the bacterial load, and PMNs infiltration as well as increasing opsonophagocytosis could lead to dramatic improvement of the infected corneas.
https://ijbms.mums.ac.ir/article_11739_717119ab89686ac780fcf4709e6c9473.pdf
2019-01-01
58
64
10.22038/ijbms.2018.31499.7643
Divalent antibody
Flagellin
Keratitis
Mmice
<i>Pseudomonas aeruginosa</i>
Pariya
Mahin Samadi
samadipariya@gmail.com
1
Department of Microbiology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
AUTHOR
Parmida
Gerami
geramiparmida@gmail.com
2
Department of Microbiology, Biology Research Center, Zanjan Branch, Islamic Azad University, Zanjan, Iran
AUTHOR
Ali
Elmi
alielmii@yahoo.com
3
Medical Biotechnology Research Center, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran
AUTHOR
korosh
khanaki
khanaki_korosh_bio@yahoo.com
4
Medical Biotechnology Research Center, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran
AUTHOR
Sobhan
Faezi
sobhan.faezi@gmail.com
5
Medical Biotechnology Research Center, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran
LEAD_AUTHOR
1. Rachwalik D, Pleyer U. [Bacterial Keratitis]. Klin Monbl Augenheilkd 2015; 232:738-744.
1
2. Taher EE, Mahmoud NF, Negm S, Abdallah I. Severe, sight threatening microbial keratitis: coinfection of acanthamoeba and Pseudomonas in contact lens associated keratitis. Adv Environ Biol 2016; 10:231-240.
2
3. Zhou C, Chen X, Wu L, Qu J. Distribution of drug-resistant bacteria and rational use of clinical antimicrobial agents. Exp Ther Med 2016; 11:2229-2232.
3
4. Lakhundi S, Siddiqui R, Khan NA. Pathogenesis of microbial keratitis. Microb Pathog 2017; 104:97-109.
4
5. Redfern RL, McDermott AM. Toll-like receptors in ocular surface disease. Exp Eye Res 2010; 90:679-687.
5
6. Chin AC, Parkos CA. Pathobiology of neutrophil transepithelial migration: implications in mediating epithelial injury. Annu Rev Pathol Mech Dis 2007; 2:111-143.
6
7. Rada B. Interactions between neutrophils and Pseudomonas aeruginosa in cystic fibrosis. Pathogens 2017; 6:1-24.
7
8. Sun Y, Karmakar M, Roy S, Ramadan RT, Williams SR, Howell S, et al. TLR4 and TLR5 on corneal macrophages regulate Pseudomonas aeruginosa keratitis by signaling through MyD88-dependent and -independent pathways. J Immunol 2010; 185:4272-4283.
8
9. Conrad JC, Gibiansky ML, Jin F, Gordon VD, Motto DA, Mathewson MA, et al. Flagella and pili-mediated near-surface single-cell motility mechanisms in Pseudomonas aeruginosa. Biophys J 2011; 100:1608-1616.
9
10. Vijay-Kumar M, Gewirtz AT. Flagellin: key target of mucosal innate immunity. Mucosal Immunol 2009; 2:197-205.
10
11. Krachler AM, Orth K. Targeting the bacteria–host interface: strategies in anti-adhesion therapy. Virulence 2013; 4:284-294.
11
12. Brimer CD, Montie TC. Cloning and comparison of fliC genes and identification of glycosylation in the flagellin of Pseudomonas aeruginosa a-type strains. J Bacteriol 1998; 180:3209-3217.
12
13. Campodonico VL, Llosa NJ, Grout M, Doring G, Maira-Litran T, Pier GB. Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines. Infect Immun 2010; 78:746-755.
13
14. Yu FS, Cornicelli MD, Kovach MA, Newstead MW, Zeng X, Kumar A, et al. Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J Immunol 2010; 185:1142-1149.
14
15. Sabharwal N, Chhibber S, Harjai K. New possibility for providing protection against urinary tract infection caused by Pseudomonas aeruginosa by non-adjuvanted flagellin ‘b’ induced immunity. Immunol Lett 2014; 162:229-238.
15
16. Gao N, Kumar A, Guo H, Wu X, Wheater M, Yu FS. Topical flagellin-mediated innate defense against Candida albicans keratitis. Invest Ophthalmol Vis Sci 2011; 52:3074-3082.
16
17. Kumar A, Hazlett LD, Yu FS. Flagellin suppresses the inflammatory response and enhances bacterial clearance in a murine model of Pseudomonas aeruginosa keratitis. Infect Immun 2008; 76:89-96.
17
18. Campodonico VL, Llosa NJ, Bentancor LV, Maira-Litran T, Pier GB. Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice. Infect Immun 2011; 79:3455-3464.
18
19. Faezi S, Safarloo M, Behrouz B, Amirmozafari N, Nikokar I, Mahdavi M. Comparison between active and passive immunization with flagellin-based subunit vaccine from Pseudomonas aeruginosa in the burned-mouse model. Iran J Clin Infect Dis 2013; 7:10-16.
19
20. Holder IA, Naglich JG. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: immunization using divalent flagella preparations. J Trauma 1986; 26:118-122.
20
21. Sabharwal N, Chhibber S, Harjai K. Divalent flagellin immunotherapy provides homologous and heterologous protection in experimental urinary tract infections in mice. Int J Med Microbiol 2016; 306:29-37.
21
22. Doring G, Dorner F. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis. Behring Inst Mitt 1997; 98:338-344.
22
23. Faezi S, Bahrmand AR, Mahdavi M, Siadat SD, Nikokar I, Sardari S, et al. High yield overexpression, refolding, purification and characterization of Pseudomonas aeruginosa type B-flagellin: an improved method without sonication. Int J Mol Cell Med 2016; 5:37-48.
23
24. Faezi S, Bahrmand AR, Mahdavi M, Siadat SD, Sardari S, Nikokar I, et al. Preparation of Pseudomonas aeruginosa alginate-flagellin immunoconjugate. Biologicals 2017; 47:11-17.
24
25. Hazlett LD. Corneal response to Pseudomonas aeruginosa infection. Prog Retin Eye Res 2004; 23:1-30.
25
26. Leenaars M, Hendriksen CF. Critical steps in the production of polyclonal and monoclonal antibodies: evaluation and recommendations. Ilar J 2005; 46:269-279.
26
27. Zaidi T, Reidy T, D’Ortona S, Fichorova R, Pier G, Gadjeva M. CD74 deficiency ameliorates Pseudomonas aeruginosa-induced ocular infection. Sci Rep 2011; 1:1-7.
27
28. Kumar A, Hazlett LD, Fu-Shin XY. Flagellin suppresses the inflammatory response and enhances bacterial clearance in a murine model of Pseudomonas aeruginosa keratitis. Infect Immun 2008; 76:89-96.
28
29. Williams R, Paterson C, Eakins K, Bhattacherjee P. Quantification of ocular inflammation: evaluation of polymorphonuclear leucocyte infiltration by measuring myeloperoxidase activity. Curr Eye Res 1982; 2:465-470.
29
30. Fleiszig SM, Kwong MS, Evans DJ. Modification of Pseudomonas aeruginosa interactions with corneal epithelial cells by human tear fluid. Infect Immun 2003; 71:3866-3874.
30
31. Kumar A, Gao N, Standiford TJ, Gallo RL, Fu-Shin XY. Topical flagellin protects the injured corneas from Pseudomonas aeruginosa infection. Microbes Infect 2010; 12:978-989.
31
32. Augustin DK, Heimer SR, Tam C, Li WY, Le Due JM, Evans DJ, et al. Role of defensins in corneal epithelial barrier function against Pseudomonas aeruginosa traversal. Infect Immun 2011; 79:595-605.
32
33. Huang LC, Reins RY, Gallo RL, McDermott AM. Cathelicidin-deficient (Cnlp−/−) mice show increased susceptibility to Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 2007; 48:4498-4508.
33
34. Atif SM, Lee SJ, Li LX, Uematsu S, Akira S, Gorjestani S, et al. Rapid CD4+ T‐cell responses to bacterial flagellin require dendritic cell expression of Syk and CARD9. Eur J Immunol 2015; 45:513-524.
34
35. Salazar-Gonzalez RM, McSorley SJ. Salmonella flagellin, a microbial target of the innate and adaptive immune system. Immunol Lett 2005; 101:117-122.
35
36. Hazlett LD, McClellan S, Goshgarian C, Huang X, Thakur A, Barrett R. The role of nitric oxide in resistance to Pseudomonas aeruginosa ocular infection. Ocul Immunol Inflamm 2005; 13:279-288.
36
37. Miller WL, Matewish MJ, McNally DJ, Ishiyama N, Anderson EM, Brewer D, et al. Flagellin glycosylation in Pseudomonas aeruginosa PAK requires the O-antigen biosynthesis enzyme WbpO. J Biol Chem 2008; 283:3507-3518.
37
ORIGINAL_ARTICLE
Computational and pharmacological investigation of novel 1,5-diaryl-1,4-pentadien-3-one derivatives for analgesic, anti-inflammatory and anticancer potential
Objective(s): The novel 1,5-diaryl-1,4-pentadien-3-one derivatives were studied for analgesic, anti-inflammatory and anticancer potential to establish their role in pain, inflammatory disorders and cancer.Materials and Methods: Two 1,5- diaryl-1,4-pentadien-3-one derivatives: (1E,4E)- 5-(4-fluoro phenyl)-1-(4-methoxyphenyl)- 2-methylpenta-1,4-dien-3-one (A2K2A17) and (1E,4E)-5-(4-nitrophenyl)-1-(4-nitrophenyl)-2-ethylhexa-1,4-dien-3-one (A11K3A11) were synthesized and characterized via 1H NMR and 13C NMR techniques. Molecular docking, anti-inflammatory, analgesic and anticancer activities were performed using Auto Doc Vina, carrageenan mediated paw edema and formalin induced chronic inflammation, acetic acid induced writhings and hotplate assay and brine-shrimp lethality assay. Results: A2K2A17 and A11K3A11 showed high computational affinities (binding energy > -9.0 Kcal/mol) against COX-1, kappa receptor and braf kinase domain. A2K2A17 and A11K3A11 exhibited moderate docking affinities (binding energy > -8.0 Kcal/mol) against COX-2, human capsaicin receptor, tumor necrosis factor, lipoxygenase, colony stimulating factor, delta receptor, cyclin dependent protein kinase-2, mitogen activated kinase, mu receptor and kit kinase domain. A2K2A17 and A11K3A11 possess low docking affinities (binding energy > -7.0 Kcal/mol) against purinoceptor, platelets-derived growth Factor-1 and vascular-endothelial growth factor. In analgesic activity, A2K2A17 (1-30 mg/kg) and A11K3A11 (1-10 mg/kg) decreased acetic acid induced writhes and prolonged the latency time (P<0.01, PConclusion: The in silico, in vitro and in vivo studies on A2K2A17 and A11K3A11 reports their computational binding affinities against targets as well as the analgesic, anti-inflammatory and the anticancer effects.
https://ijbms.mums.ac.ir/article_11740_6805427e4bd0b5d35400a91af942fdf9.pdf
2019-01-01
72
79
10.22038/ijbms.2018.31261.7536
Analgesic
Anticancer
Anti-inflammatory
In silico studies
Mice
Muhammad Sheraz
Tariq
shehraz.pharmacist@gmail.com
1
Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan
AUTHOR
Arif-ullah
Khan
arif.ullah@riphah.edu.pk
2
Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan
LEAD_AUTHOR
Amber Mahmood
Minhas
amber.mehmood@riphah.edu.pk
3
Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan
AUTHOR
Edson Rodrigues
Filho
edinho@pq.cnpq.br
4
LaBioMMi, Department of Chemistry, Federal University of São Carlos, CP 676, 13.565-905, São Carlos, SP, Brazil
AUTHOR
Zia ud
Din
zia.ufscar@gmail.com
5
LaBioMMi, Department of Chemistry, Federal University of São Carlos, CP 676, 13.565-905, São Carlos, SP, Brazil
AUTHOR
Asalm
Khan
aslamkhan_mkd@yahoo.co.uk
6
Basic Sciences Department, College of Science and Health Professions-(COSHP-J) King Saud bin Abdulaziz University for Health Sciences, Jeddah, Kingdom of Saudi Arabia
AUTHOR
1. Loeser JD, Melzack R. Pain: an overview. The Lancet 1999; 353:1607-1609.
1
2. Zulfiker AHM, Rahman MM, Hossain MK, Hamid K, Mazumder MEH, Rana MS. In vivo analgesic activity of ethanolic extracts of two medicinal plants-Scoparia dulcis L. and Ficus racemosa Linn. Biol Med 2010; 2:42-48.
2
3. Vane J, Botting R. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44:1-10.
3
4. Perianayagam JB, Sharma S, Pillai K. Anti-inflammatory activity of Trichodesma indicum root extract in experimental animals. J Ethnopharmacol 2006; 104:410-414.
4
5. Yeşilada E, Üstün O, Sezik E, Takaishi Y, Ono Y, Honda G. Inhibitory effects of Turkish folk remedies on inflammatory cytokines: interleukin-1α, interleukin-1β and tumor necrosis factor α. J Ethnopharmacol 1997; 58:59-73.
5
6. Li RW, Myers SP, Leach DN, Lin GD, Leach G. A cross-cultural study: anti-inflammatory activity of Australian and Chinese plants. J Ethnopharmacol 2003; 85:25-32.
6
7. Dharmasiri MG, Jayakody JRAC, Galhena G, Liyanage SSP, Ratnasooriya WD. Anti-inflammatory and analgesic activities of mature fresh leaves of Vitex negundo. J Ethnopharmacol 2003; 87:199-206.
7
8. Park JH, Son KH, Kim SW, Chang HW, Bae K, Kang, SS et al. Anti-inflammatory activity of Synurus deltoides. Phytother Res 2004; 18:930-933.
8
9. Amin KM, Eissa AA, Abou-Seri SM, Awadallah FM, Hassan GS. Synthesis and biological evaluation of novel coumarin-pyrazoline hybrids endowed with phenylsulfonyl moiety as anti-tumor agents. Eur J Med Chem 2013; 60:187-198.
9
10. Cabrera M, Simoens M, Falchi G, Lavaggi ML, Piro OE, Castellano EE et al. Synthetic chalcones, flavanones, and flavones as antitumoral agents: Biological evaluation and structure–activity relationships. Bioorganic Med Chem 2007; 15:3356-3367.
10
11. Anto RJ, Sukumaran K, Kuttan G, Rao MNA, Subbaraju V, Kuttan R. Anticancer and antioxidant activity of synthetic chalcones and related compounds. Cancer Lett 1995; 97:33-37.
11
12. Elias D, Beazely M, Kandepu N. Bioactivities of chalcones. Curr Med Chem 1999; 6:1125-1149.
12
13. Araico A, Terencio MC, Alcaraz MJ, Dominguez JN, León C, Ferrándiz ML. Evaluation of the anti-inflammatory and analgesic activity of Me-UCH9, a dual cyclooxygenase-2/5-lipoxygenase inhibitor. Life Sci 2007; 80:2108-2117.
13
14. Din ZU, Fill TP, de Assis FF, Lazarin-Bidóia D, Kaplum V, Garcia FP et al. Unsymmetrical 1, 5-diaryl-3-oxo-1, 4-pentadienyls and their evaluation as antiparasitic agents. Bioorganic Med Chem 2014; 22:1121-1127.
14
15. Meyer BN, Ferrigni NR, Putnam JE, Jacobsen LB, Nichols DE, McLaughlin JL. Brine shrimp: a convenient general bioassay for active plant constituents. Planta Medica 1982; 5:31-34.
15
16. Ahmed F, Selim MST, Das AK, Choudhuri MSK. Anti-inflammatory and antinociceptive activities of Lippianodiflora Linn. Pharmazie 2004; 59:329-330.
16
17. Adzu B, Amos S, Kapu S, Gamaniel K. Anti-inflammatory and anti-nociceptive effects of Sphaeranthus senegalensis. J Ethnopharmacol 2003; 84:169-173.
17
18. Padilha MM, Vilela FC, Rocha CQ, Dias MJ, Soncini R, dosSantos MH et al. Antiinflammatory properties of Morus nigra leaves. Phytother Res 2010; 24:1496-1500.
18
19. Ray SD, Ray S, Zia-Ul-Haq M, DeFeo V, Dewanjee S. Pharmacological basis of the use of the root bark of Zizyphus nummularia Aubrev (Rhamnaceae) as anti-inflammatory agent. BMC Complement Altern Med 2015; 15:1.
19
20. Cho AE, Guallar V, Berne BJ, Friesner R. Importance of accurate charges in molecular docking: quantum mechanical/molecular mechanical (QM/MM) approach. J Comput Chem 2005; 26:915-931.
20
21. Bibi G, Ullah N, Mannan N, Mirza B. Antitumor, cytotoxic and antioxidant potential of Aster thomsonii extracts. Afr J Pharm Pharmacol 2011; 2:252-258.
21
22. Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. InChemical Biology: Humana Press, New York, NY; 2015.p. 243-250.
22
23. Ayyappa B, Kanchi S, Singh P, Sabela MI, Dovey M, Bisetty K. Analytical evaluation of steviol glycosides by capillary electrophoresis supported with molecular docking studies. J Iran Chem Soc 2015; 12:127-136.
23
24. Gené RM, Segura L, Adzet T, Marin E, Iglesias J. Heterotheca inuloides: anti-inflammatory and analgesic effect. J Ethnopharmacol 1998; 60:157-162.
24
25. Bentley GA, Newton SH, Starr JB. Studies on the antinociceptive action of α‐agonist drugs and their interactions with opioid mechanisms. Br J Pharmacol 1983; 79:125-134.
25
26. Bukhari IA, Khan RA, Gilani AUH, Shah AJ, Hussain J, Ahmad VU. The analgesic, anti-inflammatory and calcium antagonist potential of Tanacetum artemisioides. Arch Pharm Res 2007; 30:303-312.
26
27. Burch RM, DeHaas C. A bradykinin antagonist inhibits carrageenan edema in rats. Naunyn-Schmiedeberg’s Arch Pharmacol 1990; 342:189-193.
27
28. Selvam C, Jachak SM. A cyclo-oxygenase (COX) inhibitory bi flavonoids from seeds of Semecarpus anacardium. J Ethnopharmacol 2004; 95:209-212.
28
29. Grosser T, Smyth E, FitzGerald GA. Antiinflammatory, antipyretic and analgesic agents. In: Goodman LS, Gilman A, Brunton LL. The Pharmacological Basis of Therapeutics, 12th ed. McGraw-Hill: New York; 2011.p. 959-971.
29
30. Igbe I, Ching FP, Eromon A. Anti-inflammatory activity of aqueous fruit pulp extract of Hunteria umbellata K. schum in acute and chronic inflammation. Acta Pol Pharm 2010; 67:81-85.
30
ORIGINAL_ARTICLE
Comparative volatile composition, antioxidant and cytotoxic evaluation of the essential oil of Zhumeria majdae from south of Iran
Objective(s): The purpose of this study was to evaluate variations in yields, volatile composition and biological activities of essential oils (EOs) obtained from the aerial parts of Zhumeria majdae collected from five localities of the south of Iran. Materials and Methods: The EOs were analyzed using gas chromatography and gas chromatography-mass spectrometry techniques. The antioxidant activity of the EOs was tested using DPPH and β-carotene/linoleic acid assays. In vitro cytotoxicity was tested against two cancer cell lines (A375 and MCF7) using MTT assay. Results: The oils yield varied from 6.3% (S2) to 10.2% (V/W) (S4). All of five investigated EOs samples presented three major compounds: linalool (24.4-34.6%), camphor (26.1-34.7%) and trans-linalool oxide (7.6-28.6%). Although the main constituents were common, their percentages were different. Among samples, S1 had a better antioxidant activity in both DPPH and β-carotene/linoleic acid methods (IC50= 8.01 and 11.77 mg/ml, respectively). In vitro cytotoxicity against two cancer cell lines of human melanoma cell line (A375) and breast cancer cell line (MCF7), showed a moderate cytotoxicity of S3 against A375 cells with IC50 value of 624 μg/ml. Conclusion: Tangezagh (S4) plant materials revealed the highest level of oil yield as the region is recommended for collecting the plant samples.Taken together, despite the weak antioxidant and moderate cytotoxic activities of tested EOs, this study suggested a proper potential for possible use of the EOs of Z. majdae for pharmaceutical and perfume industries.
https://ijbms.mums.ac.ir/article_11838_c59f73349966f7cb71a837dbd9654643.pdf
2019-01-01
80
85
10.22038/ijbms.2018.20829.5418
Antioxidant activity
Cytotoxicity
Essential oil
Lamiaceae
Zhumeria majdae
Mansoor
Saeidi
msg_saeady@yahoo.com
1
Department of Biotechnology and Plant Breeding, Faculty of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran
AUTHOR
javad
asili
asilij@mums.ac.ir
2
Department of Pharmacognosy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Seyed Ahmad
Emami
saemami@mums.ac.ir
3
Department of Pharmacognosy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Nasrin
Moshtaghi
moshtaghi@um.ac.ir
4
Department of Biotechnology and Plant Breeding, Faculty of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran
AUTHOR
Saeid
Malekzadeh-Shafaroudi
malekzadeh-s@um.ac.ir
5
Department of Biotechnology and Plant Breeding, Faculty of Agriculture, Ferdowsi University of Mashhad, Mashhad, Iran
LEAD_AUTHOR
1. Emami SA, Aghazari F. Les Phanerogames Endemiquesde la Flore d’Iran. 2011:407.
1
2. Moein S, Moein MR. Relationship between antioxidant properties and phenolics in Zhumeria majdae. J Med Plants Res 2010; 4:517-521.
2
3. Goodarzi S, Hadjiakhoondi A, Yassa N, Khanavi M, Tofighi Z. Essential oils chemical composition, antioxidant activities and total phenols of Astrodaucus persicus. Iran J Basic Med Sci 2016; 19:159-165
3
4. Majrouhi A. Chemical composition of the leaf essential oil of Zhumeria majdae growing in South Iran. Chem Nat Compd 2009; 45:429-430.
4
5. Rustaiyan A, Samadizadeh M, Habibi Z, Jakupovic J. Two diterpenes with rearranged abietane skeletons from Zhumeria majdae. Phytochemistry 1995; 39: 163-165.
5
6. Izaddoost M, Rustaiyan A. Phytochemical study on Zhumeria majdae. Fitoterapia 1983; 45:70-76.
6
7. Moein MR, Pawar RS, Khan SI, Tekwani BL, Khan IA. Antileishmanial, antiplasmodial and cytotoxic activities of 12, 16‐dideoxy aegyptinone B from Zhumeria majdae Rech. f. & Wendelbo. Phytother Res 2008; 22:283-285.
7
8. Sharififar F, Khazaeli P, Alli N, Talebian E, Zarehshahi R, Amiri S. Study of antinociceptive and anti-inflammatory activities of certain Iranian medicinal plants. J Intercult Ethnopharmacol 2012; 1: 19-24.
8
9. Hosseinzadeh H, Ramezani M, Fadishei M, Mahmoudi M. Antinociceptive, anti-inflammatory and acute toxicity effects of Zhumeria majdae extracts in mice and rats. Phytomedicine 2002; 9:135-141.
9
10. Mandegary A, Sharififar F, Abdar M, Arab-Nozari M. Anticonvulsant activity and toxicity of essential oil and methanolic extract of Zhumeria majdae rech, a unique Iranian plant in mice. Neurochemical Res 2012; 37:2725-2730.
10
11. Soltani Poor M, Rezaee M, Moradshahi A. Study on antimicrobial effects of essential oil of Zhumeria majdae Rech. f. & Wendelbo. Iran J Med Arom Plants Res 2004; 20:277-289.
11
12. Arman M, Yousefzadi M, Ebrahimi SN. Antimicrobial Activity and Composition of the Essential Oil from Zhumeria majdae Rech. f. & Wendelbo. J Essent Oil Bear Pl 2009; 12:630-634.
12
13. Ebadollahi A, Khosravi R, Sendi JJ, Mahboubi M, Kosari AA. Chemical composition of essential oil from Zhumeria majdae Rech. F. & Wendelbo and its bioactivities against Tribolium castaneum Herbst (Tenebrionidae) larvae. J Essent Oil Bear Pl 2014; 17:824-831.
13
14. Rustaiyan A, Sigari H, Bamoniri A, Weyerstahl P. Constituents of the essential oil of Zhumeria majdae Rech. Flavour Frag J 1992; 7: 273-274.
14
15. Abbaszadeh B, Teymoori M, Pouyanfar M, Rezaei M, Mafakheri S. Growth and essential oil of Mentha longifolia L. var. amphilema from different ecological conditions. Ann Biol Res 2013; 4:85-90.
15
16.Adams RP. Identification of essential oil components by gas chromatography/mass spectrometry: Allured Publishing Corporation; 2007.
16
17. Shakeri A, Khakdan F, Soheili V, Sahebkar A, Shaddel R, Asili J. Volatile composition, antimicrobial, cytotoxic and antioxidant evaluation of the essential oil from Nepeta sintenisii Bornm. Ind Crops Prod 2016; 84:224-229.
17
18. Mensor LL, Menezes FS, Leitão GG, Reis AS, Santos TCd, Coube CS, et al. Screening of Brazilian plant extracts for antioxidant activity by the use of DPPH free radical method. Phytother Res 2001; 15:127-130.
18
19. Kulisic T, Radonic A, Katalinic V, Milos M. Use of different methods for testing antioxidative activity of oregano essential oil. Food chem 2004; 85:633-640.
19
20. Smitha G, Rana VS. Variations in essential oil yield, geraniol and geranyl acetate contents in palmarosa (Cymbopogon martinii, Roxb. Wats. var. motia) influenced by inflorescence development. Ind Crop Prod 2015; 66:150-160.
20
21. Boira H, Blanquer A. Environmental factors affecting chemical variability of essential oils in Thymus piperella L. Biochem syst ecol 1998; 26:811-822.
21
22. Sharififar F, Mozaffarian V, Moshafi M, Dehghan-Nudeh G, Parandeh-Rezvani J, Mahdavi Z. Chemical composition and biological activities of Zhumeria majdae Resh. F. & wendelbo. Jundushapur J Nat Pharm Prod 2007; 3: 8-18.
22
23. Moein S, Moein MR. Relationship between antioxidant properties and phenolics in Zhumeria majdae. J Med Plants Res 2010; 4:517-521.
23
24. Kavoosi G, Rowshan V. Chemical composition, antioxidant and antimicrobial activities of essential oil obtained from Ferula assa-foetida oleo-gum-resin: effect of collection time. Food chem 2013; 138:2180-2187.
24
25. Zaouali Y, Bouzaine T, Boussaid M. Essential oils composition in two Rosmarinus officinalis L. varieties and incidence for antimicrobial and antioxidant activities. Food Chem Toxicol 2010; 48:3144-3152.
25
26. Loizzo MR, Tundis R, Menichini F, Saab AM, Statti GA, Menichini F. Cytotoxic activity of essential oils from Labiatae and Lauraceae families against in vitro human tumor models. Anticancer Res 2007; 27:3293-3299.
26
27. Chang M-Y, Shen Y-L. Linalool exhibits cytotoxic effects by activating antitumor immunity. Molecules 2014; 19:6694-6706.
27
28. Sibanda S, Chigwada G, Poole M, Gwebu ET, Noletto JA, Schmidt JM, et al. Composition and bioactivity of the leaf essential oil of Heteropyxis dehniae from Zimbabwe. J Ethnopharmacol 2004; 92:107-111.
28
29. Silva-Filho SE, de Souza Silva-Comar FM, Wiirzler LAM, do Pinho RJ, Grespan R, Bersani-Amado CA, et al. Effect of camphor on the behavior of leukocytes in vitro and in vivo in acute inflammatory response. Trop J Pharml Res 2015; 13:2031-2037.
29
30. Cherneva E, Pavlovic V, Smelcerovic A, Yancheva D. The effect of camphor and borneol on rat thymocyte viability and oxidative stress. Molecules 2012; 17:10258-10266.
30
ORIGINAL_ARTICLE
The predictive role of toll-like receptor-4 genetic polymorphisms in susceptibility to and prognosis of prostatic hyperplasia
Objective(s): This study was aimed to evaluate whether single nucleotide polymorphisms (SNPs) of TLR4 and common living habits of prostate hyperplasia (BPH) patients would affect the subjects’ risk and prognosis.Materials and Methods: We totally recruited 501 BPH patients and 964 healthy controls. The patients’ international prostate symptom score (IPSS) and quality of life assessment (QoL) were designated as the prognostic indexes for BPH patients. Altogether 7 SNPs within TLR4 were selected, and the interactions among SNPs and living habits were explained with multi-factor dimensionality reduction (MDR) modeling. Results: The mutant alleles of rs10983755 (G>A) and rs1927907 (G>A) tended to put on risk of BPH, yet the wide alleles of rs4986791 (C>T) and rs115336889 (G>C) were associated with incremental susceptibility to BPH (P<0.05). The rs10983755 (GA) and rs1927907 (GA) were suggested as the marker of non-aggressive BPH, whereas rs4986791 (TT) could symbolize aggressive BPH (P<0.05). The homozygotes of rs4986791 (TT) and rs115336889 (CC) could improve the IPSS change, and rs115336889 (CC) was also correlated with more obviously ameliorated Qol change (P<0.05). Finally, MDR modeling suggested that rs4986791 (TT) and rs115336889 (GG) shaped the genotyping combination featured by the lowest risk of BPH when smoking or drinking history was also evaluated.Conclusion: The SNPs situated within TLR4 were potent candidates for predicting risk and prognosis of BPH patients, and their interactions within environmental parameters also helped to develop effective strategies for preventing and treating BPH.
https://ijbms.mums.ac.ir/article_11819_671f8bbeb07c773062872eacc608938a.pdf
2019-01-01
86
92
10.22038/ijbms.2018.33173.7922
Prostatic hyperplasia
Toll-like receptor 4
Genetic variation
Risk
Prognosis
MDR model
Yunhua
Qiu
qiuyunhua0819@126.com
1
Department of General Surgery, Pudong Branch of Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R. China
AUTHOR
Jinzhou
Zheng
wg_zhenjinzhou@126.com
2
Department of General Surgery, Pudong Branch of Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R. China
AUTHOR
Jianfeng
Yang
trijianfengy@163.com
3
Department of General Surgery, Pudong Branch of Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R. China
AUTHOR
Feng
Li
lifeng_shh052@yeah.net
4
Department of General Surgery, Pudong Branch of Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R. China
AUTHOR
Xiqiu
Zhou
hyozhouxiqiu@126.com
5
Department of General Surgery, Pudong Branch of Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R. China
LEAD_AUTHOR
Xiaoyun
Song
gengxiao_song@yeah.net
6
Department of General Surgery, Pudong Branch of Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R. China
AUTHOR
1. Ronningen LD. Campbell’s urology, 8th ed. J Urol 2005; 173:326-326.
1
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132:474-479.
2
3. Acton JN, Salfinger SG, Tan J, Cohen PA. Outcomes of Total Laparoscopic Hysterectomy Using a 5-mm Versus 10-mm Laparoscope: A Randomized Control Trial. J Minim Invasive Gynecol 2016; 23:101-106.
3
4. Saraav I, Singh S, Sharma S. Outcome of Mycobacterium tuberculosis and Toll-like receptor interaction: immune response or immune evasion? Immunol Cell Biol 2014; 92:741-746.
4
5. O’Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol 2013; 13:453-460.
5
6. Makinen LK, Atula T, Hayry V, Jouhi L, Datta N, Lehtonen S, et al. Predictive role of Toll-like receptors 2, 4, and 9 in oral tongue squamous cell carcinoma. Oral Oncol 2015; 51:96-102.
6
7. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008; 11:91-99.
7
8. Jerrard-Dunne P, Sitzer M, Risley P, Buehler A, von Kegler S, Markus HS. Inflammatory gene load is associated with enhanced inflammation and early carotid atherosclerosis in smokers. Stroke 2004; 35:2438-2443.
8
9. Kolz M, Baumert J, Muller M, Khuseyinova N, Klopp N, Thorand B, et al. Association between variations in the TLR4 gene and incident type 2 diabetes is modified by the ratio of total cholesterol to HDL-cholesterol. BMC Med Genet 2008; 9:9-20.
9
10. Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res 2008; 20 Suppl 3:S11-18.
10
11. Moore JH. The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered 2003; 56:73-82.
11
12. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003; 19:376-382.
12
13. Lim CF, Buchan NC. Measurement of serum PSA as a predictor of symptoms scored on the IPSS for patients with benign prostatic hyperplasia. N Z Med J 2014; 127:17-24.
13
14. O’Sullivan M, Murphy C, Deasy C, Iohom G, Kiely EA, Shorten G. Effects of transurethral resection of prostate on the quality of life of patients with benign prostatic hyperplasia. J Am Coll Surg 2004; 198:394-403.
14
15. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Jr., Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387-2398.
15
16. Martin MU, Wesche H. Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. Biochim Biophys Acta 2002; 1592:265-280.
16
17. Sabroe I, Read RC, Whyte MK, Dockrell DH, Vogel SN, Dower SK. Toll-like receptors in health and disease: complex questions remain. J Immunol 2003; 171:1630-1635.
17
18. Hori M, Nishida K. Toll-like receptor signaling: defensive or offensive for the heart? Circ Res 2008; 102:137-139.
18
19. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003; 278:1561-1568.
19
20. Parker LC, Prince LR, Sabroe I. Translational mini-review series on Toll-like receptors: networks regulated by Toll-like receptors mediate innate and adaptive immunity. Clin Exp Immunol 2007; 147:199-207.
20
21. Liu H, Komai-Koma M, Xu D, Liew FY. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci U S A 2006; 103:7048-7053.
21
22. Xu D, Komai-Koma M, Liew FY. Expression and function of Toll-like receptor on T cells. Cell Immunol 2005; 233:85-89.
22
23. den Dekker WK, Cheng C, Pasterkamp G, Duckers HJ. Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis 2010; 209:314-320.
23
24. Petrick JL, Freedman ND, Demuth J, Yang B, Van Den Eeden SK, Engel LS, et al. Obesity, diabetes, serum glucose, and risk of primary liver cancer by birth cohort, race/ethnicity, and sex: Multiphasic health checkup study. Cancer Epidemiol 2016; 42:140-146.
24
25. Wild SH, Morling JR, McAllister DA, Kerssens J, Fischbacher C, Parkes J, et al. Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. J Hepatol 2016; 64:1358-1364.
25
26. Lorenz E, Frees KL, Schwartz DA. Determination of the TLR4 genotype using allele-specific PCR. Biotechniques 2001; 31:22-24.
26
27. Rau HH, Hsu CY, Lin YA, Atique S, Fuad A, Wei LM, et al. Development of a web-based liver cancer prediction model for type II diabetes patients by using an artificial neural network. Comput Methods Programs Biomed 2016; 125:58-65.
27
28. Ferwerda B, Kibiki GS, Netea MG, Dolmans WM, van der Ven AJ. The toll-like receptor 4 Asp299Gly variant and tuberculosis susceptibility in HIV-infected patients in Tanzania. AIDS 2007; 21:1375-1377.
28
29. Pulido I, Leal M, Genebat M, Pacheco YM, Saez ME, Soriano-Sarabia N. The TLR4 ASP299GLY polymorphism is a risk factor for active tuberculosis in Caucasian HIV-infected patients. Curr HIV Res 2010; 8:253-258.
29
30. Najmi N, Kaur G, Sharma SK, Mehra NK. Human Toll-like receptor 4 polymorphisms TLR4 Asp299Gly and Thr399Ile influence susceptibility and severity of pulmonary tuberculosis in the Asian Indian population. Tissue Antigens 2010; 76:102-109.
30
31. Xue Y, Zhao ZQ, Wang HJ, Jin L, Liu CP, Wang Y, et al. Toll-like receptors 2 and 4 gene polymorphisms in a southeastern Chinese population with tuberculosis. Int J Immunogenet 2010; 37:135-138.
31
32. Marengo A, Rosso C, Bugianesi E. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Annu Rev Med 2016; 67:103-117.
32
33. Raff EJ, Kakati D, Bloomer JR, Shoreibah M, Rasheed K, Singal AK. Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases. J Clin Transl Hepatol 2015; 3:9-16.
33
34. Yang Z, Zhou L, Wu LM, Lai MC, Xie HY, Zhang F, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol 2011; 18:1243-1250.
34
35. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69:138-147.
35
36. Rohrmann S, Crespo CJ, Weber JR, Smit E, Giovannucci E, Platz EA. Association of cigarette smoking, alcohol consumption and physical activity with lower urinary tract symptoms in older American men: findings from the third National Health And Nutrition Examination Survey. BJU Int 2005; 96:77-82.
36
ORIGINAL_ARTICLE
Histone deacetylase inhibitory and cytotoxic activities of the constituents from the roots of three species of Ferula
Objective(s): Histone deacetylase inhibitory and cytotoxic activities of 18 naturally occuring terpenoids (ferutinin, stylosin, tschimgine and guaiol), coumarins (umbelliprenin, farnesiferone B, conferone, feselol, ligupersin A, conferdione, conferoside) and sulfur-containing derivatives (latisulfies A-E, persicasulphides A and C) from the roots of three species of Ferula (Ferula latisecta, Ferula ovina and Ferula flabelliloba) were evaluated.Materials and Methods: The cytotoxic activity of compounds was evaluated against human cancer cell lines (HeLa, HCT116, A2780 and A549) by AlamarBlue® assay using vorinostat as the positive control. On the other hand, we aimed to evaluate their inhibitory activities against pan-HDAC.Results: The methanolic extract of the roots of F. flabelliloba was subjected to silica gel column chromatography. Further purification by preparative thin-layer chromatography (PTLC) and semipreparative RP-HPLC yielded twelve known compounds (1-12). This is the first report on the isolation of guaiol (1), persicasulphide C (3) and conferoside (10) from the roots of F. flabelliloba. Six compounds including persicasulfide A, conferone, feselol, latisufide C, conferoside and ferutinin showed cytotoxic activity with IC50 values in the range of 11.61-49.40 μM against cancer cells and pan-HDAC inhibitory activity with IC50 values in the range of 1.06-35.27 μM.Conclusion: Results indicated that persicasulfide A (2), conferone (6) and feselol (7) showed moderate cytotoxicity with IC50 values in the range of 11.76-39.24 μM against cancer cells and potent pan-HDAC inhibitory activity with IC50 values in the range of 1.06-10.73 μM. Conferone was more active than others with a higher potency for HDAC inhibition (1.06- 1.17 μM).
https://ijbms.mums.ac.ir/article_11891_f2fd54e699cb3953b80f468302a7c728.pdf
2019-01-01
93
98
10.22038/ijbms.2018.34338.8151
Apiaceae
Ferula latisecta
Ferula ovina
Ferula flabelliloba
Histone deacetylase inhibitors
Cytotoxic activities
Saba
Soltani
soltani_s@razi.tums.ac.ir
1
Department of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Gholamreza
Amin
gh_amin@yahoo.com
2
Department of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Mohammad Hossein
Salehi-Sourmaghi
s_surmaghi@yahoo.com
3
Department of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Mehrdad
Iranshahi
iranshahim@mums.ac.ir
4
Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
1. Roche J, Bertrand P. Inside HDACs with more selective HDAC inhibitors. Eur J Med Chem 2016; 121:451-483.
1
2. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009; 8:1409-1420.
2
3. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38-51.
3
4. Pimenov M, Leonov M. The Asian Umbelliferae biodiversity database (ASIUM) with particular reference to South-West Asian taxa. Turk J Bot 2004; 28:139-145.
4
5. Kajimoto T, Yahiro K, Nohara T. Sesquiterpenoid and disulphide derivatives from Ferula assa-foetida. Phytochemistry 1989; 28:1761-1763.
5
6. Iranshahi M, Noroozi S, Behravan J, Karimi G, Schneider B. Persicasulphide C, a new sulphur-containing derivative from Ferula persica. Nat Prod Res 2009; 23:1584-1588.
6
7. Iranshahi M, Hassanzadeh-Khayat M, Fazly Bazzaz BS, Sabeti Z, Enayati F. High content of polysulphides in the volatile oil of Ferula latisecta Rech. F. et Aell. fruits and antimicrobial activity of the oil. J Essent Oil Res 2008; 20:183-185.
7
8. Sattar Z, Iranshahi M. Phytochemistry and pharmacology of Ferula persica Boiss.: A review. Iran J Basic Med Sci 2017; 20:1-8.
8
9. Nazari Z, Iranshahi M. Biologically active sesquiterpene coumarins from Ferula species. Phytother Res 2011; 25:315-323.
9
10. Iranshahi M, Fata A, Emami B, Shahri BJ, Fazly Bazzaz BS. In vitro antifungal activity of polysulfides-rich essential oil of Ferula latisecta fruits against human pathogenic dermatophytes. Nat Prod Commun 2008; 3:1543-1546.
10
11. Soltani S, Amin G-R, Salehi-Sourmaghi MH, Schneider B, Lorenz S, Iranshahi M. Sulfur-containing compounds from the roots of Ferula latisecta and their cytotoxic activities. Fitoterapia 2018; 124:108-112.
11
12. Balasubramanian S, Verner E, Buggy JJ. Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 2009; 280:211-221.
12
13.Bertrand P. Inside HDAC with HDAC inhibitors. Eur J Med Chem 2010; 45:2095-2116.
13
14. Ciossek T, Julius H, Wieland H, Maier T, Beckers T. A homogeneous cellular histone deacetylase assay suitable for compound profiling and robotic screening. Anal Biochem 2008; 372:72-81.
14
15. Iranshahi M, Famili A, Bassarello C, Piacente S, Pizza C. Purification and structure elucidation of compounds from the roots of Ferula ovina Boiss. J Med Plants Res 2010; 4:72-80.
15
16. O’brien J, Wilson I, Orton T, Pognan F. Investigation of the AlamarBlue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000; 267:5421-5426.
16
17. Marek L, Hamacher A, Hansen FK, Kuna K, Gohlke H, Kassack MU, et al. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem 2013; 56:427-436.
17
18. Zwick V, Allard PM, Ory L, Simões‐Pires CA, Marcourt L, Gindro K, et al. UHPLC‐MS‐based HDAC assay applied to bio‐guided microfractionation of fungal extracts. Phytochem Anal 2017; 28:93-100.
18
19. Iranshahi M, Amin G, Shafiee A. A new coumarin from Ferula persica. Pharm Biol 2004; 42:440-442.
19
20. Iranshahi M, Barthomeuf C, Bayet-Robert M, Chollet P, Davoodi D, Piacente S, et al. Drimane-type sesquiterpene coumarins from Ferula gummosa fruits enhance doxorubicin uptake in doxorubicin-resistant human breast cancer cell line. J tradit complement med 2014; 4:118-125.
20
21. Münchberg U, Anwar A, Mecklenburg S, Jacob C. Polysulfides as biologically active ingredients of garlic. Org Biomol Chem 2007; 5:1505-1518.
21
22. Shokoohinia Y, Chianese G, Appendino G, Di Marzo V, De Petrocellis L, Ghannadi A, et al. Some like it pungent and vile. TRPA1 as a molecular target for the malodorous vinyl disulfides from asafoetida. Fitoterapia 2013; 90:247-251.
22
23. Ho R, Nievergelt A, Pires CS, Cuendet M. Histone deacetylases as cancer chemoprevention targets for natural products. Stud Nat Prod Chem 2012; 38:247-267.
23
24. Nian H, Delage B, Ho E, Dashwood RH. Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds. Environmental and molecular mutagenesis 2009; 50:213-221.
24
25. Nian H, Delage B, Pinto JT, Dashwood RH. Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis 2008; 29:1816-1824.
25
26. Barthomeuf C, Demeule M, Grassi J, Saidkhodjaev A, Beliveau R. Conferone from Ferula schtschurowskiana enhances vinblastine cytotoxicity in MDCK-MDR1 cells by competitively inhibiting P-glycoprotein transport. Planta Med 2006; 72:634-639.
26
27. Valiahdi SM, Iranshahi M, Sahebkar A. Cytotoxic activities of phytochemicals from Ferula species. DARU J Pharm Sci 2013; 21:39.
27
28. Cheraghi O, Dehghan G, Mahdavi M, Rahbarghazi R, Rezabakhsh A, Charoudeh HN, et al. Potent anti-angiogenic and cytotoxic effect of conferone on human colorectal adenocarcinoma HT-29 cells. Phytomedicine 2016; 23:398-405.
28
29. Okada T, Tanaka K, Nakatani F, Sakimura R, Matsunobu T, Li X, et al. Involvement of P‐glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug‐resistant osteosarcoma and Ewing’s sarcoma cells. In J Cancer 2006; 118:90-97.
29
30. Kim YK, Kim NH, Hwang JW, Song Y-J, Park Y-S, Seo D-W, et al. Histone deacetylase inhibitor apicidin-mediated drug resistance: involvement of P-glycoprotein. Biochem Biophys Res Commun 2008; 368:959-964.
30
31. Xiao JJ, Foraker AB, Swaan PW, Liu S, Huang Y, Dai Z, et al. Efflux of Depsipeptide FK228 (FR901228, NSC-630176) Is Mediated by P-Glycoprotein and Multidrug Resistance-Associated Protein 1. J Pharmacol Exp Ther 2005; 313:268-276.
31
32. Shahwar D, Raza MA, Shafiq-Ur-Rehman, Abbasi MA, Atta-Ur-Rahman. An investigation of phenolic compounds from plant sources as trypsin inhibitors. Nat Prod Res 2012; 26:1087-1093.
32
33. Shee C, Sharma AK. Purification and characterization of a trypsin inhibitor from seeds of Murraya koenigii. J Enzyme Inhib Med Chem 2007; 22:115-120.
33
ORIGINAL_ARTICLE
Hydrogen sulfide treatment protects against renal ischemia-reperfusion injury via induction of heat shock proteins in rats
Objective(s): Hydrogen sulfide (H2S) attenuates ischemia-reperfusion injury (IRI) in different organs. However, its mechanism of action in renal IRI remains unclear. The present study investigated the hypothesis that H2S attenuates renal IRI via the induction of heat shock proteins (HSPs).Materials and Methods: Adult Wistar rats were subjected to unilateral renal ischemia for 45 min followed by reperfusion for 6 hr. One group of rats underwent I/R without treatment, one group was administered 150 μmol/l sodium hydrosulfide (NaHS) prior to I/R, one group was injected with 100 mg/kg quercetin (an HSP inhibitor) intraperitoneally prior to I/R, and another group received quercetin prior to I/R and treatment with NaHS following I/R. Two other groups underwent a sham operation and one of them received 150 μmol/l NaHS following the sham operation whereas the other received no treatment. Renal function and histological changes were compared and relevant indices of oxidative stress, apoptosis, and inflammation were examined. Results: IRI increased serum creatinine and blood urea nitrogen concentrations, promoted lipid peroxidation by elevating malondialdehyde levels, suppressed superoxide dismutase activity, stimulated inflammation by inducing NF-kB, IL-2, and TLR-4 expression, and increased renal apoptosis. Levels of HSP70, heme-oxygenase-1 (HO-1) and HSP 27 were increased following IRI and reversed following H2S treatment. H2S attenuated changes observed in pathology, lipid peroxidation, inflammation, and apoptosis following IRI. The administration of quercetin reversed all protective effects of H2S. Conclusion: The present study indicated that H2S protected renal tissue against IRI induced lipid peroxidation, inflammation, and apoptosis, which may be attributed to the upregulation of HSP 70, HO-1, and HSP 27.
https://ijbms.mums.ac.ir/article_11759_d220917fbc699eb843c57f56555a8383.pdf
2019-01-01
99
105
10.22038/ijbms.2018.29706.7170
Hydrogen sulfide
Heat shock protein 70
Heat shock protein 27
Heme oxygenase 1
Ischemia-reperfusion injury
Rat
Renal
Yang
Du
174510704@qq.com
1
Department of Urology, Renmin Hospital of Wuhan University, Hubei, China
AUTHOR
Xiu-heng
Liu
phoenixneo@126.com
2
Department of Urology, Renmin Hospital of Wuhan University, Hubei, China
LEAD_AUTHOR
Heng-cheng
Zhu
wangw1987@126.com
3
Physician, Department of Urology, Renmin Hospital of Wuhan University, Hubei, China
AUTHOR
lei
wang
huanghoubao@126.com
4
Physician, Department of Urology, Renmin Hospital of Wuhan University, Hubei, China
AUTHOR
Zhi-shun
Wang
zhy_1982zhy@126.com
5
Physician, Department of Urology, Renmin Hospital of Wuhan University, Hubei, China
AUTHOR
Jin-zhuo
ning
1315816132@qq.com
6
Physician, Department of Urology, Renmin Hospital of Wuhan University, Hubei, China
AUTHOR
Cheng-cheng
Xiao
136913159@qq.com
7
Physician, Department of Urology, Renmin Hospital of Wuhan University, Hubei, China
AUTHOR
1. Kosieradzki M, Rowinski W. Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. Transplant Proc 2008;40:3279-3288.
1
2. Pruchnicki MC, Dasta JF. Acute renal failure in hospitalized patients: part I. Ann Pharmacother 2002;36:1261-1267.
2
3. Kunduzova OR BPPN. Regulation of JNK/ERK activation, cell apoptosis, and tissue regeneration by monoamine oxidases after renal ischemia‑reperfusion. FASEB J 2002:16: 1129‑1131.
3
4. Akoh JA. Transplant nephrectomy. World J Transplantation 2011:1: 4‑12.
4
5. Kimura H. The physiological role of hydrogen sulfide and beyond. Nitric Oxide 2014;41:4-10.
5
6. Purandhar K, Jena PK, Prajapati B, Rajput P, Seshadri S. Understanding the role of heat shock protein isoforms in male fertility, aging and apoptosis. World J Mens Health 2014;32:123-132.
6
7. Zhang PL, Lun M, Schworer CM, Blasick TM, Masker KK, Jones JB, et al.. Heat shock protein expression is highly sensitive to ischemia-reperfusion injury in rat kidneys. Ann Clin Lab Sci 2008;38:57-64.
7
8. Guo Q, Du X, Zhao Y, Zhang D, Yue L, Wang Z. Ischemic postconditioning prevents renal ischemia reperfusion injury through the induction of heat shock proteins in rats. Mol Med Rep 2014;10:2875-2881.
8
9. Stricher F, Macri C, Ruff M, Muller S. HSPA8/HSC70 chaperone protein: structure, function, and chemical targeting. Autophagy 2013;9:1937-1954.
9
10. Wang CF, Wang ZY, Li JY. Dual protective role of HO-1 in transplanted liver grafts: a review of experimental and clinical studies. World J Gastroenterol 2011;17:3101-3108.
10
11. Ziemann E, Zembron-Lacny A, Kasperska A, Antosiewicz J, Grzywacz T, Garsztka T, et al.. Exercise training-induced changes in inflammatory mediators and heat shock proteins in young tennis players. J Sports Sci Med 2013;12:282-289.
11
12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408.
12
13. Arya R, Mallik M, Lakhotia SC. Heat shock genes - integrating cell survival and death. J Biosci 2007;32:595-610.
13
14. Seemampillai B, Germack R, Felkin LE, McCormack A, Rose ML. Heat shock protein-27 delays acute rejection after cardiac transplantation: an experimental model. Transplantation 2014;98:29-38.
14
15. Riehle KJ, Hoagland V, Benz W, Campbell JS, Liggitt DH, Langdale LA. Hepatocellular heme oxygenase-1: a potential mechanism of erythropoietin-mediated protection after liver ischemia-reperfusion injury. Shock 2014;42:424-431.
15
16. Zhang L, Gan W, An G. Influence of Tanshinone IIa on heat shock protein 70, Bcl-2 and Bax expression in rats with spinal ischemia/reperfusion injury. Neural Regen Res 2012;7:2882-2888.
16
17. Li C, Hu M, Wang Y, Lu H, Deng J, Yan X. Hydrogen sulfide preconditioning protects against myocardial ischemia/reperfusion injury in rats through inhibition of endo/sarcoplasmic reticulum stress. Int J Clin Exp Pathol 2015;8:7740-7751.
17
18. Zhang Q, Fu H, Zhang H, Xu F, Zou Z, Liu M, et al.. Hydrogen sulfide preconditioning protects rat liver against ischemia/reperfusion injury by activating Akt-GSK-3beta signaling and inhibiting mitochondrial permeability transition. PLoS One 2013;8:e74422.
18
19. Gurbuxani S, Bruey JM, Fromentin A, Larmonier N, Parcellier A, Jaattela M, et al.. Selective depletion of inducible HSP 70 enhances immunogenicity of rat colon cancer cells. Oncogene 2001;20:7478-7485.
19
20. Liao W, Li X, Mancini M, Chan L. Proteasome inhibition induces differential heat shock protein response but not unfolded protein response in HepG2 cells. J Cell Biochem 2006;99:1085-1095.
20
21. Lepore DA, Knight KR, Anderson RL, Morrison WA. Role of priming stresses and HSP 70 in protection from ischemia-reperfusion injury in cardiac and skeletal muscle. Cell Stress Chaperones 2001;6:93-96.
21
22. Cao YA, Kusy S, Luong R, Wong RJ, Stevenson DK, Contag CH. Heme oxygenase-1 deletion affects stress erythropoiesis. PLoS One 2011;6:e20634.
22
23. Yang Y, Song HL, Zhang W, Wu BJ, Fu NN, Dong C, et al.. Heme oxygenase-1-transduced bone marrow mesenchymal stem cells in reducing acute rejection and improving small bowel transplantation outcomes in rats. Stem Cell Res Ther 2016;7:164-172.
23
24. Xiong J, Wang K, Yuan C, Xing R, Ni J, Hu G, et al.. Luteolin protects mice from severe acute pancreatitis by exerting HO-1-mediated anti-inflammatory and antioxidant effects. Int J Mol Med 2017;39:113-125.
24
25. Jia XM, Zhou ZX, Huang JJ, Chu W, Guan QH. [Protective effects of the induction of heme oxygenase-1 on ischemia reperfusion lung injury: in vivo experiment with rats]. Zhonghua Yi Xue Za Zhi 2007;87:1211-1213.
25
26. Katavetin P, Inagi R, Miyata T, Shao J, Sassa R, Adler S, et al.. Erythropoietin induces heme oxygenase-1 expression and attenuates oxidative stress. Biochem Biophys Res Commun 2007;359:928-934.
26
27. Steel R, Doherty JP, Buzzard K, Clemons N, Hawkins CJ, Anderson RL. Hsp72 inhibits apoptosis upstream of the mitochondria and not through interactions with Apaf-1. J Biol Chem 2004;279:51490-51499.
27
28. Braunersreuther V, Jaquet V. Reactive oxygen species in myocardial reperfusion injury: from physiopathology to therapeutic approaches. Curr Pharm Biotechnol 2012;13:97-114.
28
29. Wang Y, Zhang ZZ, Wu Y, Zhan J, He XH, Wang YL. Honokiol protects rat hearts against myocardial ischemia reperfusion injury by reducing oxidative stress and inflammation. Exp Ther Med 2013;5:315-319.
29
30. Ma JQ, Liu CM, Qin ZH, Jiang JH, Sun YZ. Ganoderma applanatum terpenes protect mouse liver against benzo(alpha)pyren-induced oxidative stress and inflammation. Environ Toxicol Pharmacol 2011;31:460-468.
30
31. Wong ET, Tergaonkar V. Roles of NF-kappaB in health and disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2009;116:451-465.
31
ORIGINAL_ARTICLE
Detection of co-harboring OXA-58 and NDM-1carbapenemase producing genes resided on a same plasmid from an Acinetobacter pittii clinical isolate in China
Objective(s): Acinetobacter pittii has become an emerging opportunistic noscomial pathogen worldwide with multi-drug resistance. In the present study, an A. pittii strain was isolated from bronchoalveolar lavage fluid sample harboring both OXA-58 and NDM-1carbapenemase producing genes. The mechanisms of carbapenem resistance of the A. pittii strain was investigated.Materials and Methods: Carbapenemase producing genes were examined by PCR and DNA sequencing. S1-PFGE was used to localize carbapenemase encoding genes. Filter mating and electrotransformation were used to investigate the transferability of such carbapenemase encoding genes between different strains. Genetic surroundings of blaOXA-58 and blaNDM-1 genes were detected as well.Results: The A. pittii strain, carrying both OXA-58 and NDM-1 carbapenemase encoding genes, was resistant to all β-lactam antibiotics, while suscepitible to ciprofloxacin, levofloxacin, tobramycin, cotrimoxazole and tigecycline. Southern blot hybridization for the blaOXA-58 and blaNDM-1 gene indicated that the two genes locate in the same plasmid with molecular weight of 310.1-336.5kb. BlaOXA-58 was located in an ISAba3-blaOXA-58-ISAba3-like structure, and the blaNDM-1 gene cluster was embedded in an ISAba125-aphA6- blaNDM-1-bleMBL-ΔtrpF-dsbC-cutA structure sequentially.Conclusion: In the present study, it is first reported an A. pittii clincal strain in China, co-harboring OXA-58 and NDM-1 carbapenemase producing genes residing on a same plasmid. In hospital and community settings, it is of great significance and urgence to increase the surveillance of these kinds of organisms.
https://ijbms.mums.ac.ir/article_11601_fdc64df4f44c22dc332146c122711696.pdf
2019-01-01
106
111
10.22038/ijbms.2018.28934.6994
Acinetobacter pittii
Carbapenemase
Co-harboring
NDM-1
OXA-58
Yili
Chen
13570260173@163.com
1
Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, 510080, Guangzhou, Guangdong, China
AUTHOR
Penghao
Guo
acasia@163.com
2
Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, 510080, Guangzhou, Guangdong, China
AUTHOR
Han
Huang
huanghan007@163.com
3
Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, 510080, Guangzhou, Guangdong, China
AUTHOR
Yongxin
Huang
huangyongxin@163.com
4
Department of Laboratory Medicine, Zhongshan Medical School of Sun Yat-sen University, 510080, Guangzhou, Guangdong, China
AUTHOR
Zhongwen
Wu
wuzhongwen@163.com
5
Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, 510080, Guangzhou, Guangdong, China
AUTHOR
Kang
Liao
nancy20150919@163.com
6
Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, 510080, Guangzhou, Guangdong, China
LEAD_AUTHOR
1. Zhou S, Chen X, Meng X, Zhang G, Wang J, Zhou D, et al. “Roar” of blaNDM-1 and “silence” of blaOXA-58 co-exist in Acinetobacter pittii. Sci Rep 2015;5:8976.
1
2. Poirel L, Bonnin RA, Nordmann P. Genetic basis of antibiotic resistance in pathogenic Acinetobacter species. IUBMB LIFE 2011;63:1061-1067.
2
3. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006;12:826-836.
3
4. Karah N, Sundsfjord A, Towner K, Samuelsen O. Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii. Drug Resist Updat 2012;15:237-247.
4
5. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. NAT REV MICROBIOL 2007;5:939-951.
5
6. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J Antimicrob Chemother 2009;63:55-59.
6
7. Moro M, Nizzero P, Biancardi A, Baldan R, Scarpellini P, Curti C, et al. An outbreak caused by multidrug-resistant OXA-58-positive Acinetobacter baumannii in an intensive care unit in Italy. J Hosp Infect 2008;68:97-99.
7
8. Castanheira M, Wanger A, Kruzel M, Deshpande LM, Jones RN. Emergence and clonal dissemination of OXA-24- and OXA-58-producing Acinetobacter baumannii strains in Houston, Texas: report from the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol 2008;46:3179-3180.
8
9. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46:1254-1263.
9
10. Cornaglia G, Giamarellou H, Rossolini GM. Metallo-beta-lactamases: a last frontier for beta-lactams? Lancet Infect Dis 2011;11:381-393.
10
11. Gupta V. Metallo beta lactamases in Pseudomonas aeruginosa and Acinetobacter species. Expert Opin Investig Drugs 2008;17:131-143.
11
12. Krizova L, Bonnin RA, Nordmann P, Nemec A, Poirel L. Characterization of a multidrug-resistant Acinetobacter baumannii strain carrying the blaNDM-1 and blaOXA-23 carbapenemase genes from the Czech Republic. J Antimicrob Chemother 2012;67:1550-1552.
12
13. Nemec A, Krizova L. Carbapenem-resistant Acinetobacter baumannii carrying the NDM-1 gene, Czech Republic, 2011. Euro Surveill 2012;17.
13
14. Zhang C, Qiu S, Wang Y, Qi L, Hao R, Liu X, et al. Higher isolation of NDM-1 producing Acinetobacter baumannii from the sewage of the hospitals in Beijing. PLOS ONE 2014;8:e64857.
14
15. Huang TW, Lauderdale TL, Liao TL, Hsu MC, Chang FY, Chang SC, et al. Effective transfer of a 47 kb NDM-1-positive plasmid among Acinetobacter species. J Antimicrob Chemother 2015;70:2734-2738.
15
16. Kamolvit W, Derrington P, Paterson DL, Sidjabat HE. A case of IMP-4-, OXA-421-, OXA-96-, and CARB-2-producing Acinetobacter pittii sequence type 119 in Australia. J CLIN MICROBIOL 2015;53:727-730.
16
17. Pagano M, Poirel L, Martins AF, Rozales FP, Zavascki AP, Barth AL, et al. Emergence of NDM-1-producing Acinetobacter pittii in Brazil. Int J Antimicrob Agents 2015;45:444-445.
17
18. Sun FJ, Shi HQ, Zhang XB, Fang YD, Chen YC, Chen JH, et al. Detection of carbapenemase-encoding genes among clinical isolates of Pseudomonas aeruginosa in a Chinese burn unit. J Burn Care Res 2013;34:453-458.
18
19. Rodriguez-Martinez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009;53:4783-4788.
19
20. Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H. OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 2009;53:5035-5038.
20
21. Zhou S, Chen X, Meng X, Zhang G, Wang J, Zhou D, et al. “Roar” of blaNDM-1 and “silence” of blaOXA-58 co-exist in Acinetobacter pittii. Sci Rep 2015;5:8976.
21
22. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J COMPUT BIOL 2012;19:455-477.
22
23. Lin MF, Lan CY. Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases 2014;2:787-814.
23
24. Yang J, Chen Y, Jia X, Luo Y, Song Q, Zhao W, et al. Dissemination and characterization of NDM-1-producing Acinetobacter pittii in an intensive care unit in China. Clin Microbiol Infect 2012;18:E506-E513.
24
25. Poirel L, Marque S, Heritier C, Segonds C, Chabanon G, Nordmann P. OXA-58, a novel class D {beta}-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother 2005;49:202-208.
25
26. Coelho J, Woodford N, Afzal-Shah M, Livermore D. Occurrence of OXA-58-like carbapenemases in Acinetobacter spp. collected over 10 years in three continents. Antimicrob Agents Chemother 2006;50:756-758.
26
27. Peleg AY, Franklin C, Walters LJ, Bell JM, Spelman DW. OXA-58 and IMP-4 carbapenem-hydrolyzing beta-lactamases in an Acinetobacter junii blood culture isolate from Australia. Antimicrob Agents Chemother 2006;50:399-400.
27
28. Castanheira M, Wanger A, Kruzel M, Deshpande LM, Jones RN. Emergence and clonal dissemination of OXA-24- and OXA-58-producing Acinetobacter baumannii strains in Houston, Texas: report from the SENTRY Antimicrobial surveillance program. J Clin Microbiol 2008;46:3179-3180.
28
29. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J Antimicrob Chemother 2009;63:55-59.
29
30. Poirel L, Nordmann P. Genetic structures at the origin of acquisition and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-58 in Acinetobacter baumannii. Antimicrob Agents Chemother 2006;50:1442-1448.
30
31. Chen TL, Wu RC, Shaio MF, Fung CP, Cho WL. Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii. Antimicrob Agents Chemother 2008;52:2573-2580.
31
32. Chen TL, Chang WC, Kuo SC, Lee YT, Chen CP, Siu LK, et al. Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU. Antimicrob Agents Chemother 2010;54:3107-3112.
32
33. Boo TW, Crowley B. Detection of blaOXA-58 and blaOXA-23-like genes in carbapenem-susceptible Acinetobacter clinical isolates: should we be concerned? J Med Microbiol 2009;58:839-841.
33
34. Liu LL, Ji SJ, Ruan Z, Fu Y, Fu YQ, Wang YF, et al. Dissemination of blaOXA-23 in Acinetobacter spp. in China: main roles of conjugative plasmid pAZJ221 and transposon Tn2009. Antimicrob Agents Chemother 2015;59:1998-2005.
34
35. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009;53:5046-5054.
35
36. Tran DN, Tran HH, Matsui M, Suzuki M, Suzuki S, Shibayama K, et al. Emergence of New Delhi metallo-beta-lactamase 1 and other carbapenemase-producing Acinetobacter calcoaceticus-baumannii complex among patients in hospitals in Ha Noi, Viet Nam. Eur J Clin Microbiol Infect Dis 2017;36:219-225.
36
37. Bharadwaj R, Joshi S, Dohe V, Gaikwad V, Kulkarni G, Shouche Y. Prevalence of New Delhi metallo-beta-lactamase (NDM-1)-positive bacteria in a tertiary care centre in Pune, India. Int J Antimicrob Agents 2012;39:265-266.
37
38. Jones LS, Toleman MA, Weeks JL, Howe RA, Walsh TR, Kumarasamy KK. Plasmid carriage of bla NDM-1 in clinical Acinetobacter baumannii isolates from India. Antimicrob Agents Chemother 2014;58:4211-4213.
38
39. Chen Y, Cui Y, Pu F, Jiang G, Zhao X, Yuan Y, et al. Draft genome sequence of an Acinetobacter genomic species 3 strain harboring a bla(NDM-1) gene. J Bacteriol 2012;194:204-205.
39
40. Bonnin RA, Poirel L, Nordmann P. New Delhi metallo-beta-lactamase-producing Acinetobacter baumannii: a novel paradigm for spreading antibiotic resistance genes. Future Microbiol 2014;9:33-41.
40
41. Poirel L, Bonnin RA, Nordmann P. Analysis of the resistome of a multidrug-resistant NDM-1-producing Escherichia coli strain by high-throughput genome sequencing. Antimicrob Agents Chemother 2011;55:4224-4229.
41
42. Karthikeyan K, Thirunarayan MA, Krishnan P. Coexistence of blaOXA-23 with blaNDM-1 and armA in clinical isolates of Acinetobacter baumannii from India. J Antimicrob Chemother 2010;65:2253-2254.
42
43. Krizova L, Bonnin RA, Nordmann P, Nemec A, Poirel L. Characterization of a multidrug-resistant Acinetobacter baumannii strain carrying the blaNDM-1 and blaOXA-23 carbapenemase genes from the Czech Republic. J Antimicrob Chemother 2012;67:1550-1552.
43
44. Chen Z, Qlu S, Wang Y, Wang Y, Liu S, Wang Z, et al. Coexistence of blaNDM-1 with the prevalent blaOXA23 and blaIMP in pan-drug resistant Acinetobacter baumannii isolates in China. CLIN INFECT DIS 2011;52:692-693.
44
45. Ang GY, Yu CY, Cheong YM, Yin WF, Chan KG. Emergence of ST119 Acinetobacter pittii co-harbouring NDM-1 and OXA-58 in Malaysia. Int J Antimicrob Agents 2016;47:168-169.
45
46. Hu H, Hu Y, Pan Y, Liang H, Wang H, Wang X, et al. Novel plasmid and its variant harboring both a bla(NDM-1) gene and type IV secretion system in clinical isolates of Acinetobacter lwoffii. Antimicrob Agents Chemother 2012;56:1698-1702.
46
47. Poirel L, Dortet L, Bernabeu S, Nordmann P. Genetic features of blaNDM-1-positive Enterobacteriaceae. Antimicrob Agents Chemother 2011;55:5403-5407.
47
48. Wailan AM, Paterson DL. The spread and acquisition of NDM-1: a multifactorial problem. Expert Rev Anti Infect Ther 2014;12:91-115.
48
49. Bogaerts P, Huang TD, Rezende DCR, Bouchahrouf W, Glupczynski Y. Could Acinetobacter pittii act as an NDM-1 reservoir for Enterobacteriaceae? J Antimicrob Chemother 2013;68:2414-2415.
49
50. Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D beta-lactamases. Antimicrob Agents Chemother 2010;54:24-38.
50